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Leptin is a polypeptide hormone, secreted principally by adipose tissue, which
functions as an afferent signal in a feedback loop to maintain body weight and energy
homeostasis. In addition to its well documented effects on food intake and energy
expenditure, leptin modulates the function of many other physiological systems in
mammals, through actions in the central nervous system and periphery. Remarkably,
despite extensive studies on leptin receptor expression, the physiological biodistribution
of the hormone remains essentially unknown. In order to characterize the distribution
leptin in mammals, we have developed methodologies to radiolabel the hormone and
visualize its biodistribution using positron emission tomography (PET). Two
complementary techniques were developed to label leptin using the positron emitting
isotopes 68Ga and 18F. 68Ga labeling was accomplished by lysine-directed conjugation
with the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
followed by chelation of the isotope. 18F labeling was accomplished using a site-specific,
two step labeling procedure in which an aminooxy moiety was introduced at the Cterminus of leptin using expressed protein ligation (EPL), which was subsequently
derivitized with 18F-4-fluorobenzaldehyde in an aniline accelerated radiochemical

oximation reaction. These probes were used for PET imaging in mice, rats, and in rhesus
macaques. PET imaging in these organisms revealed that the hormone was rapidly taken
up by the cortex of the kidney, bone marrow, and visceral organs. Uptake in the kidney
was partially saturable with cold ligand, and was not mediated by leptin receptor (ObR).
Subsequent analysis in with a kidney specific knockout of the multiligand endocytic
transporter megalin revealed loss of leptin in the urine, which was confirmed using PET
imaging. Thus, megalin is required for the uptake of leptin in the proximal convoluted
tubule within the cortex of the kidney. Subsequent biodistribution experiments revealed
that the hormone was taken up by the brain, spleen, liver, fat, and lungs in mice, and that
this uptake was leptin receptor dependant. Furthermore, PET imaging in rhesus macaques
revealed that leptin was absorbed by the bone marrow and liver. Thus, leptin may activate
and modulate hematopoiesis by direct action on either hematopoietic precursors or the
stromal support tissue. Thus, novel physiologically significant interactions of the
hormone leptin were revealed using PET.
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Chapter 1. Introduction

1.1 Leptin: a circulating factor regulating fat homeostasis

Energy and body weight homeostasis in mammals is regulated with remarkable
precision. While an average man takes in approximately one million kcal per year, the
expected weight gain of the same individual is under 0.5 kilograms, an energy increase of
only 1560 kcal. This small weight gain represents only 0.2% of energy intake1. Thus,
food intake and energy expenditure must be nearly equal, suggesting the existence of a
feedback system which regulates this coupling. Nevertheless, there is a clear variation in
the set point of this system between individuals. Obesity is defined as a body mass index
(BMI, defined as the weight of an individual in kg/height in m squared) of over 30, and is
associated with significant health risks, most prominently cardiovascular disease and
diabetes2. Obesity has increased dramatically worldwide over the last 30 years, and
current estimates suggest that at least 35% of adults in the United States are obese3. A
series of studies on twins have revealed that the variation in body weight is 50-90%
genetic, a factor underappreciated by the general public4. Nevertheless, there is a
continual increase in average BMI and obesity, implying that environmental factors must
also play a role. Thus, obesity is a result of genetic susceptibility, coupled with an
“obesigenic” environment in which inexpensive, high calorie, palatable foods are readily
available5. An understanding of these genetic and environmental factors, and the
development of effective interventions to control them, is of paramount importance for
public health in the 21st century.
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The role of the hypothalamus in body weight and energy homeostasis has been
known since the 1940’s. Bilateral lesions introduced in rats in the lateral hypothalamus
completely inhibited food intake to the point that the animals die of starvation6.
Conversely, lesions in the ventromedial nucleus of the hypothalamus cause hyperphagia.
Based on these observations, Kennedy proposed the existence of a circulating factor
which could signal the level of fat to the hypothalamus7. The spontaneously occurring
obese mouse mutants ob and db (named for obese and diabetes) provided additional clues
about the nature of these factors. By fusing the circulatory systems of ob and wild type
animals (parabiosis), the obese phenotype of the ob animal could be abrogated8. By
contrast, the db mouse did not lose weight when parabiosed with the wild type animal. In
fact, the animal fused to the db mouse lost weight and eventually died of starvation9.
Furthermore, when the ob and db animals were fused, the ob animal lost weight, while
the db did not. Collectively, these experiments suggested that the ob mouse was lacking
Kennedy’s circulating satiety factor, and that the db animal was lacking a receptor for a
satiety factor. However, without a molecular mechanism to explain these observations,
little advance could be made in understanding the basic organization of fat metabolism.
The positional cloning of the ob gene in 1994 by Friedman and co workers
ushered in a new era in which rapid progress could be made in unraveling the regulation
of fat and energy homeostasis10. The Ob gene encodes a 167 amino acid protein, termed
leptin (after the Greek “leptos” for thin), which, following processing of the signal
sequence and secretion, circulates as a 146 amino acid protein of approximately 16 kDa.
Several lines of evidence rapidly established that leptin could serve as Kennedy’s satiety
factor: leptin is expressed in adipose tissue11,12, its expression is correlated with fat mass
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in rodents and BMI in humans13, and treatment of the ob mouse with leptin rapidly
corrects the obese phenotype14. Shortly thereafter, the leptin receptor (ObR) was cloned
from a cDNA library from choroid plexus and was found to be contained within the db
locus15. Subsequent studies demonstrated that ObR is expressed in the hypothalamus
(among many other tissues)16, that leptin is transported into the brain by a saturable
mechanism17, and that deletion of the gene in neurons was sufficient to generate an obese
phenotype18. Thus, leptin is a circulating factor, produced by adipose tissue in proportion
to lipid mass, which can signal the level of fat stores in the body and produce a
compensatory response19.
A human pedigree of individuals with an inactivating mutation in the leptin gene
causing morbid obesity was described in 1997 by O’Rahilly and co-workers20, confirming
that leptin is essential for normal energy homeostasis in humans. These individuals
display a complex syndrome of obesity, hyperphagia, diabetes, central hypogonadism,
abnormalities of T-cell number and function, hypothyroidism, and other endocrine
abnormalities, which is corrected by replacement therapy with the hormone21. A similar
syndrome is observed in individuals with loss of function mutations in ObR22. Several
other genetic abnormalities of signaling downstream of leptin which cause morbid
obesity have been described in humans, and these relatively rare occurrences have helped
identify the roles played by these mediators in normal fat homeostasis23,24.
Leptin’s mechanism of action suggested that it could function as an obesity drug.
However, the weight loss induced by the hormone was less profound than expected,
suggesting that obese humans were resistant to its actions25. The mechanism of leptin
resistance in humans remains unclear, but it is likely that several factors play a role.
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Obese humans have high circulating levels of leptin, but the high peripheral level is not
necessarily reflected in the CNS, where the crucial hypothalamic leptin receptors are
located26. Thus, transport of leptin into the brain may be reduced in obese individuals.
Central leptin resistance may also play a role, as leptin signaling in the CNS also appears
to be attenuated in various models of obesity27. Additionally, signaling pathways in
neural or peripheral tissues downstream of leptin may be affected.
The mechanism of leptin resistance in humans remains cryptic, but recently
described combination therapies with the peptide amylin are promising for the treatment
of obesity28,29. Additionally, leptin is used in the clinic for treatment of the fat deficiency
seen in lipodistrophy, and may potentially be used for hypothalamic amenorrhea30,31.
Further understanding of leptin physiology and resistance may help in the development of
novel therapeutics. Thus, a more thorough characterization of the physiology of leptin
production, biodistribution, and function is of central importance to the understanding of
fat homeostasis and obesity in modern man.

1.2 Leptin and Leptin Receptors (ObR)
Leptin circulates in mice and humans as a 146 amino acid protein of
approximately 16 kDa32. The crystal structure of leptin revealed that it is a four-helix
bundle with structural homology to long chain cytokines such as LIF, IL-6, and hGH
(Figure 1)33. The lone post-translational modification is a disulfide bond between C96 and
C146. Although no high-resolution structure of leptin receptor has yet been reported, its
extracellular domain is a class I cytokine receptor, with sequence homology to the
extracellular gp130 subunits of the IL-6, G-CSF, and LIF receptors. The extracellular
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portion of leptin receptor is common to all isoforms, and consists of two cytokine
receptor homologous domains (CRH1), an IgD like domain, and two fibronectin type III
domains (Figure 2). Based on extensive mutagenesis and homology modeling, Peelman
et al. have proposed a plausible model of leptin binding to leptin receptor in which
signaling is activated in a 2:4 leptin:leptin receptor complex34. However, not all evidence
supports this model35, and in the absence of further structural information the true
mechanism of leptin:leptin receptor binding will remain obscure.

Figure 1. The crystal structure of leptin. The disulfide bond between C96 and C146 is
indicated in blue. The protein is a four helix bundle with homology to other cytokines
such as IL-6.
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Leptin receptor is expressed as several different isoforms, with varying
transmembrane and intracellular domains (Figure 2). By far the best characterized is
ObRb, which is the longest of the isoforms, and is abundantly expressed in the
hypothalamus. Abnormal splicing of the intracellular domain, causing a functional
replacement of ObRa for ObRb, is the mutation underlying the obesity seen in the db
mouse16. ObRb has a juxtamembrane segment which binds the JAK2 kinase, and two
tyrosine residues (985 and 1138) which can be phosphorylated by this kinase (Figure 2).
ObRb also activates STAT3, MAPK, PI3K, and AMPK downstream of JAK236. The
short isoforms, ObRa, ObRc, ObRd, and ObRf, lack the full signaling capacity of this
receptor37,38. ObRa and ObRc are highly expressed in choroid plexus and cerebral
microvessels, suggesting that they may function in transporting leptin into the CNS,
although this has not been proven39,40. ObRe lacks a transmembrane domain altogether,
and circulates in the bloodstream where it binds to leptin, possibly modulating the half
life of the hormone41-43.
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Figure 2. Simplified diagram of leptin receptor, long isoform (ObRb). Leptin binding to
the IgD and CHR2 domains of the extracellular portion of the receptor drives recruitment
of JAK2 to the juxtamembrane segment of the receptor. JAK2 then trans-phosphorylates
the JAK2 associated with another receptor subunit, as well as STAT3, SHP-2, and other
substrates. Engagement of the receptor by leptin drives gene transcription and repression
via STAT3 and also activates MAPK, PI3K, and AMPK pathways. The figure represents
full length ObRb, while ObRa, c, d and f lack the intracellular domain (with the exception
of the JAK2 juxtamembrane binding segment), and ObRe lacks both the transmembrane
and intracellular regions.
A variety of other non-ObR leptin-binding proteins have been described. For
example, leptin binds to siglec-6, a sialic acid binding lectin abundantly expressed on the
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placenta44. Additionally, leptin may bind to and be inactivated by C-reactive protein
(CRP)45, although the results and conclusions of this study are controversial46-48. Leptin
also binds to α-2 macroglobulin, an abundant serum protein, with an apparent affinity of
2 μM49. Finally, leptin binds to megalin, a receptor abundantly expressed on kidney
tubules50. Remarkably, the physiological significance of these binding partners, as well as
most of the isoforms of the leptin receptor, remains unknown.

1.3 Leptin action and binding in the CNS and in the periphery
Several lines of evidence support the concept that leptin signaling in the CNS is
both required and sufficient to produce many of leptin’s effects51. Firstly, an ObR gene
deletion in neurons in mice was sufficient to produce a syndrome nearly identical to that
of total leptin receptor deficiency18. Secondly, the reintroduction of ObRb in neurons
rescues the obese phenotype seen in db mice.52 Thirdly, direct injection of leptin into the
CNS is much more potent at inducing its effects than peripheral injection53. Fourthly,
lesions of the hypothalamus are sufficient to produce syndromes of hyperphagia and
obesity54. Finally, many leptin resistant animal models have defective leptin signaling in
the hypothalamus27.
There are two well-characterized populations of leptin-responsive neurons in the
arcuate nucleus of the hypothalamus. The first produces two potent orexigenic peptides,
agouti-related peptide (AgRP) and neuropeptide Y (NPY). These AgRP neurons are
inhibited by leptin, and ablation of this population causes life threatening hypophagia55.
The other population of neurons, which produce pro-opiomelanocortin (POMC), is
activated by leptin. POMC is cleaved by proteases to generate a variety of peptides
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termed melanocortins56. These POMC-derived melanocortins are agonists for
melanocortin G-protein coupled receptors (principally MC3R and MC4R in the CNS),
while AgRP is an antagonist at these receptors57. The AgRP and POMC neurons project
to neurons expressing MC3R and MC4R in the lateral hypothalamus and paraventricular
nucleus, which in turn produce a variety of downstream mediators of leptin action. Thus,
leptin acts simultaneously on two populations of neurons, activating AgRP neurons,
while inhibiting POMC neurons. The net effect of this program is to activate the central
melanocortin signaling system, which causes anorexia and energy expenditure19,56,58.
While the direct action of leptin on the CNS is clearly required for its
physiological outputs, strong evidence for direct peripheral actions of leptin has also
accumulated (fig 3). ObRb mRNA is transcribed in several peripheral tissues, including
pancreas59, lung37, kidney37,60, placenta61, adrenal glands60, T lymphocytes62, hematopoietic
stem cells63, endothelial cells64, fat65, and bone65. Furthermore, leptin administration in
rats induces STAT3 phosphorylation in fat, muscle, and liver66. However, these data must
be approached with caution as they do not exclude an indirect effect through the CNS,
acting through similar downstream signaling mediators. Nevertheless, the presence of
leptin receptor RNA, coupled with evidence of activation of signaling downstream of this
receptor, strongly suggests that leptin acts directly on peripheral tissues.
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Figure 3. A simplified summary of peripheral and central actions of leptin.

The specific physiological effects of leptin on peripheral tissues have also been
investigated (Figure 3). A tissue specific gene deletion of leptin receptor in the pancreas
resulted in enhanced early phase insulin secretion, which was attenuated by high fat diet,
suggesting that leptin modulates islet β-cell function67. Leptin also has direct effects on
immune cells in vitro: it shifts T-cells towards a Th1 phenotype62 and stimulates T-cell
proliferation68. Ob mice are resistant to the development of autoimmune disease69, and
have defective cell mediated immune systems62, suggesting that leptin plays a permissive
role in regulating the immune system in vivo. Furthermore, leptin, acting in concert with
parathyroid hormone, may stimulate fetal lung to produce surfactant70. In adipose tissue,
leptin may signal in a paracrine manner, which is suppressed in leptin resistant diet
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induced obese mice71,72. The physiological function of leptin signaling in adipose tissue is
not yet understood, but may include increased lipolysis and glucose utilization73. In the
placenta, which is itself a source of leptin, the hormone induces the release of proinflammatory cytokines74. In muscle, leptin stimulates the phosphorylation of AMPK,
increasing fatty acid oxidation, an effect that may be mediated in part by direct action on
the muscle tissue75. Leptin may also act as an angiogenic factor in vivo by directly
activating the proliferation of endothelial cells64. Thus, it is clear that in addition to the
well established role of leptin in regulating food intake and energy expenditure in the
hypothalamus, the hormone also directly modulates the physiology of peripheral organs.
Collectively, leptin appears to signal the nutritional and energy status of the organism to
peripheral tissues. A reduction of leptin, such as would be seen during starvation, alters
the function of peripheral organs so as to conserve energy, and downregulates nonessential functions.
The binding of leptin to sites in the CNS and in the periphery has also been
studied extensively. In this analysis, animals are sacrificed, and tissue sections are
prepared. Radiolabeled leptin can then be bound to the sections, and visualized using
autoradiography. Due to the fixation process, this analysis allows for visualization of both
extracellular and intracellular leptin receptors. The initial cloning of leptin receptor was
accomplished following autoradiographic localization of leptin binding in the choroid
plexus, and subsequent expression cloning from a choroid plexus cDNA library15. This
binding pattern was subsequently replicated by several other groups76-78. In the brain,
leptin binds to various nuclei in the hypothalamus, including the arcuate, paraventricular,
and ventromedial nuclei79,80. High affinity binding sites in the medulla of the kidney have
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also been identified81. Leptin binding sites were also identified in the adrenal medulla82.
In a particularly thorough study, Dal Farra et al. characterized leptin binding sites in mice
at several stages of development83. Binding was found in the lung, digestive tract, liver,
kidney, cartilage, spleen, and in the choroid plexus. Taken together, these experiments
show that leptin binds to ObR in peripheral and central tissues, where it activates
signaling, producing a diversity of outputs to regulate energy homeostasis, as well as to
conserve energy in times of starvation.

1.4 The application biodistribution studies to leptin
One approach to integrate the enormous amount of data on the divergent functions
of leptin would be to study the biodistribution of the hormone in live animals. This
methodology could confirm the validity of studies of leptin activity and ex vivo binding
in various peripheral or central tissues, as well as discovering new functions of the
hormone in an unbiased approach. Additionally, specific hypotheses about the molecular
identity of leptin binding partners or transporters could be assessed using appropriate
animal models.
Before the development of high resolution in vivo imaging technology, the
method traditionally used to assess these parameters was biodistribution analysis. In this
technique, a radiolabeled tracer is injected into an animal, and after a predetermined
period of time, the animal is sacrificed, and the radioactivity in various tissues counted.
These data complement tissue binding and mRNA expression data (section 1.3), as they
account for a physiological pattern of cell surface receptor expression. By far the most
commonly used tracer for this purpose is 125I-leptin. 125I-leptin has been used for the
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purpose of studying leptin half-life and clearance in mice, rats, and rhesus monkeys. The
half-life of leptin has been found to follow bi-exponential decay, which presumably
represents rapidly cleared free leptin, and more slowly cleared leptin bound to circulating
receptors (mainly ObRe). The first phase half-life is very fast, under 10 minutes in rats,
while the second phase is about one hour84-86. These and other studies also revealed that
leptin was cleared from the circulation by the kidney, as expected for small
polypeptides50,87-90. This is consistent with the fact that human patients with end-stage
renal disease have relative hyperleptinemia when the values are corrected for their BMI91.
In addition to binding in the kidney and choroid plexus, one study also suggested that
leptin was taken up in the bone marrow in mice92.
Leptin transport into the CNS has also been extensively studied using
biodistribution methodology. A saturable, low capacity transport system into the CNS has
been defined in cerebral microvessels by using 125I leptin17. However, the transporter
responsible for this phenomenon has not yet been identified. While ObRa is abundantly
expressed at the capillary endothelium and choroid plexus78, and is able to transcytose
leptin in cell lines93, isolated brain preparations from rats lacking ObR have identical
transport rates compared to normal rats and mice40,94 . Thus, the commonly cited
observation that mice and rats lacking ObR have reduced transport of leptin into the brain
is likely an artifact of the compensatory high levels of leptin in these animals39,95. The
identity of this molecular transporter is crucial to understanding leptin resistance, as
reduced transport of leptin into the CNS has been proposed to underlie leptin resistance
seen in obese humans26.
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1.5 In vivo imaging methodologies and application to leptin
A live animal imaging approach has advantages over the classical biodistribution
approach in studying leptin biology. In particular, quantitative kinetic information of
uptake in various organs can be readily obtained, and probes can be readily translated
into studies in nonhuman primates and into the clinic. To date there have been two live
animal imaging studies of leptin biodistribution, in different contexts. Karonen et al.
studied the biodistribution of 123I labeled leptin in rabbits using dynamic gamma
imaging96. In this study, the authors saw uptake in the lungs, kidney, liver, and choroid
plexus. However, the relatively low resolution of the images makes the conclusions
difficult to verify and interpret. McCarthy et al. labeled leptin with the positron emitting
isotope 68Ga using the chelator diethylene triamine pentaacetic acid (DTPA)97. They
subsequently imaged the biodistribution of leptin when injected into the intrathecal space
in baboons using positron emission tomography (PET). In this study the authors found
that the intrathecally injected leptin moved rostrally to the cranium, but that there was
considerable variation in the three animals tested. Thus, to date there has been no
comprehensive study of leptin biodistribution using in vivo imaging technologies.
Several live animal imaging approaches could be used to study leptin biology. In
principle, fluorescence, bioluminescence, magnetic resonance imaging (MRI), and
positron emission tomography (PET) could readily be applied to studying leptin biology.
For example, a fluorescently labeled leptin derivative could be imaged in vivo or a leptin
derivative labeled with gadolinium could be imaged using MRI. However, in comparing
the available imaging technologies for this purpose, positron emission tomography (PET)
has several advantages (table 1)98. It has the highest sensitivity of currently available
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imaging techniques, while still retaining excellent spatial resolution, and ease of
quantification. Additionally, PET can be readily translated into large animal systems and
into the clinic. Thus, we chose to study leptin biodistribution using PET.

Imaging modality

Form of
energy

Spatial
resolution

Sensitivity

Quantification

Organism

Fluorescence

Visible/NIR

2-10 mm

+++

low

mouse

Magnetic
resonance (MRI)

Radio wave

sub mm

+

medium

mouse,
primate,
human

Bioluminescence
imaging

Visible/NIR

3-10 mm

variable

low

mouse

Positron emission
tomography
(PET)

Annihilation
photons

1-10 mm

++++

high

mouse,
primate,
human

Table 1. A comparison of live animal imaging techniques. Adapted from Levin, C.S.,
Eur. J. Nucl Med. Mol. Imaging98.
1.6 Technical aspects of PET tracer development: Isotopes, labeling chemistries
Positron emission tomography requires that the tracer of interest be labeled with a
positron emitting isotope. Positron emitting isotopes, such as 18F or 64Cu, are intrinsically
unstable and decay, producing positrons, which travel a short distance in tissue before
finding their antiparticle, the electron. When positron/electron pair collide, they
annihilate, producing two antiparallel photons of 511 keV. These photons are
subsequently counted by a detector. Following various corrections to account for
scattering effects, an image can be reconstructed with excellent spatial resolution (in the
1-2 mm range). Careful design of a tracer is crucial to obtaining high-resolution images
that correspond to the authentic biodistribution99.
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Probably the single most important decision regarding PET tracer development is
isotope selection. An variety of isotopes are currently available (table 2) with differing
properties100. The half-life of an isotope is an important parameter, as in practice any
labeling technique which cannot be accomplished in 3 half-lives of the isotope is unlikely
to be successful. Thus, very short -lived isotopes such as 15O and 13N are not used
frequently. A second important feature is the percentage of positrons emitted by an
isotope: other modes of decay can confound the imaging results and produce undesirable
radiation exposure. Additionally, the energy of the positron emitted (Bmax) limits the
resolution of the image obtained, as high energy positrons undergo various scattering
events prior to annhilation101. The final factor regarding isotope selection is the method of
generation, either via cyclotron, generator, or reactor. Cyclotrons are relatively common
in nuclear medicine, radiology, and oncology departments due to the popularity of 18F fluorodeoxyglucose (FDG), the most commonly used PET tracer. Nuclear reactors will
remain rare due to safety considerations. A generator is a smaller device containing a
fixed amount of a parent isotope, which decays continually, to a positron emitting isotope
of shorter half-life. Thus, the generator produces a constant supply of a desired isotope,
which can be used approximately every 3-4 half-lives. Based on the considerations of
half -life, resolution, and method of production, 18F has emerged as the leading isotope
for PET, with 11C being nearly as widely used for small molecule tracers. Other isotopes
are more commonly used for specialized applications- for example radiometals are
widely used for peptide and protein labeling (see below)102.
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Bmax
(positron
energy,
MeV)
0.96

Percent
positron
emission

Production
method

100

cyclotron

13N
9.97 min
1.2
100
15O
122.2 sec
1.73
100
18F
109.8 min
0.63
99
64Cu
12.8 hours
0.65
18
68Ga
68.3 min
1.92
89
76Br
15.9 hours
3.94
54
86Y
14.7 hours
3.14
34
124I
4.17 days
2.14
23
Table 2. Commonly used positron emitting isotopes.

cyclotron
cyclotron
cyclotron
cyclotron
generator
cyclotron
cyclotron
cyclotron

Isotope

Half-life

11C

20.5 min

PET radiochemistry is fundamentally similar to organic/inorganic chemistry, but
has several key differences. Firstly, owing to the short half-life of the isotopes, the
labeling must be performed rapidly. Secondly, the reactions must be performed at trace or
“no-carrier added” level: 10 MBq of 18F, a typical dose injected into a mouse in a PET
experiment, is only 200 fmol of the isotope. Thus, in practice not all reactions are
applicable to PET radiolabeling. Finally, positrons produce highly energetic, penetrating
gamma rays, which for safety reasons require extensive shielding and precautions.
The generation of a high quality PET tracer requires that several design
considerations be observed. Firstly, the tracer itself must be chemically and biologically
similar to the normal, unmodified molecule which it is attempting to mimic. Frequently,
for small molecular tracers, it is possible to generate a tracer with no changes made to the
intact structure of the molecule. However, this is not always possible, and the case of
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peptide and protein labeling, nonnative prosthetic reactive groups must be installed103.
Therefore, it is crucial to test if a modified tracer retains its biological activity. This is
generally accomplished by generating a “cold” version of the molecule in which the
positron-emitting isotope is replaced with the naturally occurring one, and testing its
activity in various biological assays. Finally, the specific activity (defined as the amount
of radioactivity in Curies or Becquerels per mole) determines which interactions can be
visualized. If the tracer has low specific activity, a large molar amount of tracer must be
used to enable visualization, potentially saturating the binding sites which are to be
studied104. However, with careful selection of isotope, labeling site, conjugation
chemistry, and technique, high quality, high specific activity positron emitting tracers
can, in principle, be generated with biological activity intact.

1.7 Chemical and radiochemical aspects of protein labeling for PET imaging
Proteins are both particularly desirable and challenging targets for labeling with
positron emitting isotopes. The challenge of labeling them arises from the fact that there
is no generally applicable method for radio-conjugation without destroying their activity,
and that since they generally produce their effect in vivo with high affinity (typically low
nanomolar), the labeled tracer must have very high specific activity. Furthermore,
proteins can not generally be exposed to extreme conditions, such as high temperature,
microwave heating, or treatment with organic solvents since these will denature them.
Thus, protein labeling with positron emitting isotopes is generally accomplished with
robust reactions which can proceed at lower temperatures.
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The most commonly used technique for labeling proteins with positron emitting
isotopes is the chelation of radiometals, such as 68Ga and 64Cu102,105. This can be
accomplished by appending a chelator to the protein and subsequently complexing the
modified protein with the radiometal of interest. By far the most commonly used chelator
for this purpose is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)106. A
wide variety of metals, such as the postiron emitting 64Cu or 68Ga, can be incorporated,
and the metal complexes formed with this chelator are stable over the course of days in
live animals. Furthermore, DOTA derivatives for labeling lysine and cysteine side chains
are commercially available. Thus, DOTA, and other metal chelators such as diethylene
triamine pentaacetic acid (DTPA) are widely used for protein labeling with positron
emitting isotopes.
Radiohalogens are the second most frequently used nuclides for postiron emitting
isotope labeling of proteins. 124I, 75Br, 76Br, and 18F are all positron emitters with useful
half lives. Iodine and bromine isotopes can be installed using conventional
radiohalogenation chemistry, for example using Chloramine-T, Iodogen, or enzymatic
peroxidases107. However, the low percentage of positrons emitted and high energy of
those positrons emitted by these isotopes (table 2) results in low quality images in a
micro-PET setting. Owing to the favorable imaging properties of the isotope, 18F labeling
of peptides and proteins is particularly desirable. However, standard radiohalogenation
chemistry is not applicable, as synthesis of 18F-F2 can only be accomplished in the
presence of carrier, resulting in very low specific activity. Nucleophilic 18F- is highly
unreactive in water due to solvation, and thus cannot be directly installed on proteins via
currently available techniques. Recently, promising methods for one step labeling of
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small molecules and peptides have been developed based on the incorporation of boronic
acids or organosilicon, and treatment with fluoride anion in organic solvents108,109. At
present, these techniques are not applicable to protein labeling due to the requirement for
organic solvents109, or very high concentrations of the reactive precursor108. Thus, 18F is
currently conjugated to proteins using multistep reactions, in which 18F is first introduced
into an organic reactive group which is subsequently conjugated to the protein of
interest110,111. Due to the optimal imaging properties of 18F these labeling methodologies
are an area of intense interest in the field of radiochemistry. The currently available
techniques for peptide and protein radiofluorination, as well as our own developments in
this area will be covered in chapter 2.
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Chapter 2. Design, synthesis and characterization of 18F and 68Ga labeled leptin
tracers

2.1 Labeling of proteins for PET and design considerations for isotopic labeling of
leptin
PET has emerged as a powerful tool for in vivo imaging in clinical medicine as
well as in basic research. PET imaging is complementary to other in vivo imaging
techniques such as single photon emission computed tomography (SPECT), fluorescence
imaging, bioluminescence imaging, and magnetic resonance imaging (MRI), and in
particular it offers good resolution, high sensitivity, ready translation to clinical studies,
and ease of quantification98,99,112. PET requires that a probe of interest be labeled with a
positron emitting nuclide, such as 18F, 11C, or 68Ga100. 18F is a particularly desirable
radionuclide for PET imaging owing to its intermediate half-life of 109.7 minutes, its
routine availability by biomedical cyclotron production, and the high resolution of images
obtained. Proteins and peptides are widely used tracers in PET and a variety of
techniques, principally based on the incorporation of radiometals, have been developed to
label them102. The interest in peptide imaging and the superior imaging properties of 18F
has led to the development of several approaches for labeling synthetic peptides with this
isotope109-111,113-121. Protein labeling using 18F synthons targeting lysine122-125 residues has
also been developed and applied to a variety of substrates. However, in contrast to the
aforementioned peptide labeling approaches, these protein labeling techniques give rise
to a variety of labeled products, and it is difficult to characterize the structure or function
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of the tracer. Site-specific labeling of proteins is particularly desirable as it allows
unambiguous biophysical and activity-based characterization of a homogeneous product,
leading to reproducibility in labeling and imaging126,127. Accordingly, the generation of
site-specifically labeled proteins for molecular imaging has become an area of active
research126. Recently, site-specific 18F labeling of proteins on unique cysteine residues has
also been described128-132. These site-specifically radiolabeled proteins are promising
reagents for molecular imaging for biodistribution studies in model animals as well as in
the clinic.
In order to study leptin biodistribution using PET, we developed two
complementary labeled tracers, which we term 18F-FBA-leptin and 68Ga-DOTA-leptin.
While no high resolution crystal structure of a leptin-leptin receptor complex has been
reported, mutagenesis studies have established the residues of leptin which are required
for both receptor binding and activation34,133,134. The lysine residues of the protein, and
both the C and N termini of the molecule, are mainly distributed elsewhere on the
structure from the receptor binding region33,135. We therefore rationalized that either an
amine-directed or a site-specific C-terminal labeling strategy would produce a labeled
leptin derivative with unaltered bioactivity (Figure 4). Thus, we have developed an
amine-directed labeling method for 68Ga labeling using the chelator DOTA, and a sitespecific 18F labeling method using a two step expressed protein ligation/oximation
protocol.
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Fig 4. Design, synthesis, and biological activity of the tracers 18F-FBA-leptin and 68GaDOTA-leptin. Two views of the structure of leptin (PDBID 1AX8), with side chains
rendered as spheres for residues which are known to be required for ObR binding
(yellow). The potential labeling sites for 68Ga-DOTA-leptin (lysine side chains and the Nterminus) are rendered as red spheres, while the C-terminus, the labeling site of 18F-FBAleptin, is rendered as a blue sphere.
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2.2 Development of 68Ga-DOTA-leptin
Radiometallation of proteins is a widely used technique in radiochemistry, with
68

Ga and 64Cu being the most commonly used postiron emitting isotopes for labeling102.

68

Ga is obtained from a 68Ge generator, making it an attractive method for labeling. 68Ga

labeling of a protein was first reported in 1975 with an albumin labeling strategy136, and
the key findings of this study remain the crucial guidelines for 68Ga labeling today - 68Ga
labeling is optimal at acidic pH (2.5-4.5) due to the formation of insoluble Ga(OH)3
complexes at higher pH, and must be accomplished rapidly due to the short 68 minute
half life. The development of the high affinity chelators diethylene triamine pentaacetic
acid (DTPA) and 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
allowed more practical and extensive use of this isotope, owing to the inertness and
stability of the chelated metal complexes106,137,138. DOTA chelates gallium via a
hexadentate interaction in which the metal is coordinated axially by two nitrogens and
two opposite carboxylates, and equatorially by the remaining two nitrogens139. Recently
68

Ga-DOTA labeled peptides have become popular for use in PET and biodistribution

studies, and are promising reagents for use in clinical diagnosis104,140-143.
Thus, in order to study leptin biodistribution, we developed a lysine directed
labeling approach to conjugate the isotope 68Ga to leptin using the metal chelator DOTA
(Figure 7a). Using DOTA-NHS, we found that the level of labeling of the protein could
be controlled by varying the molar excess of DOTA-NHS used in the reaction (Figure 5).
Out of eight possible labeling sites (seven lysines plus the N-terminus), we found that we
could conjugate and average of one to four copies of DOTA to leptin by varying the
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reaction conditions. In preliminary studies, we found that radiolabeling was most
efficient using the most heavily modified tracer (data not shown). Thus, we pursued this
compound, with an average of four copies of DOTA per leptin molecule (figure 7b) for
use as a tracer in studying leptin biodistribution.
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Figure 5. ESI-MS reconstructs of DOTA-NHS : Leptin conjugation reactions. All
reactions were performed at pH 7.5, 5 mg/mL leptin, with the indicated number of
equivalents of DOTA-NHS.
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In order to verify the bioactivity of our DOTA-modified protein, its activity was
tested in several assays. A cell-based assay was developed using a 293 cell line stably
transfected with ObRb, and luciferase under the control of a STAT3-dependant element
(Figure 6). As expected based on the design considerations (Figure 4), the ability of the
modified protein to activate leptin receptor STAT3-dependant signaling was unaltered in
this cell line (Figure 7c). Additionally, the ability of DOTA-leptin to induce weight loss
in leptin deficient (Ob/Ob) mice was identical to unmodified recombinant leptin over a
period of 9 days, when administered via subcutaneous osmotic pumps (Figure 7d). Thus,
labeling leptin with DOTA using an amine directed labeling strategy does not alter its
bioactivity.
Radiolabeling of the protein using 68Ga proceeded in good yield (decay corrected
yield of 25.7% ± 4.9% s.d., n = 30, specific activity of 5.5 – 11 GBq/μmol, scheme 1),
affording a product that was always greater than 90% pure (Figure 7e). As expected
based on the extraordinary inertness of DOTA-metal complexes, the tracer was stable in
vivo as assessed by HPLC analysis of the serum recovered from a mouse injected with
68

Ga-DOTA-leptin 30’ prior (Figure 7e). Finally, the 68Ga labeling procedure did not

abrogate receptor-binding activity, as the labeled protein bound to the aforementioned
cell line expressing ObR, and the binding could be displaced by excess competing cold
leptin (Figure 7f). Thus, leptin can be labeled with 68Ga, preserving the biological activity
of the hormone.
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Figure 6. Schematic of ObRb-STAT3-Luciferase assay. A 293 cell line is stably
transfected with ObRb and luciferase under the control of a STAT3 dependant element.
In this cell line, leptin binds to and activates ObRb, which recruits JAK2 to the receptor.
Phosphorylated leptin receptor subsequently recruits STAT3, which is phosphorylated by
receptor-bound JAK2. Phosphorylated STAT3 dissociates from the receptor, translocates
to the nucleus, where it activates luciferase gene transcription. Luciferase activity can
then be quantified using a luminometer. Thus, luciferase is produced in a leptin dosedependant manner.
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Figure 7. a) Schematic of 68Ga-DOTA-leptin tracer. b) ESI-MS of DOTA-leptin
revealing an average of 4 copies of DOTA per leptin molecule. c) in vitro bioactivity of
DOTA-leptin was compared to recombinant leptin using a 293 cell line stably expressing
leptin receptor (ObRb) and a luciferase reporter under STAT3 responsive element. The
EC50 for activation was 0.42 to 0.55 nM for recombinant leptin and 0.54 to 0.66 nM (95%
confidence intervals, n=2 ± s.d.) for DOTA-leptin. d) DOTA-leptin induces weight loss
to a similar extent as recombinant leptin in ob/ob mice (n=4 ± s.e.m., dose = 450 ng/hr).
e) Radiochemical HPLC analysis of purified 68Ga-DOTA-leptin (blue) and serum
recovered from a mouse 30 minutes post injection with 68Ga-DOTA-leptin, demonstrating
the stability of the tracer in vivo. f) Cell binding assay of 68Ga-DOTA-leptin using a 293
cell line overexpressing ObRb, in the presence or absence of 1 μM competing
recombinant leptin (n=3, ± s.d.).
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Scheme 1. Schematic of method used to label DOTA-leptin with 68Ga.

2.3. Development of expressed protein ligation to site-specifically label the Cterminus of leptin
In designing a site-specific leptin 18F labeling protocol, various options were
considered. While in principle a cysteine directed labeling approach could produce site
specifically 18F labeled leptin, we found that the introduction of additional cysteines in
the protein led to difficulties in refolding and protein purification (data not shown).
Fortunately, the C-terminal amino acid of leptin is cysteine, which in principle would
allow for direct modification of the protein using expressed protein ligation (EPL)144.
EPL is a semisynthetic technique based on the earlier development of native chemical
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ligation, in which a recombinantly expressed protein α-thioester is fused to any peptide
containing an N-terminal cysteine. In native chemical ligation, an unprotected peptide
with an N-terminal cysteine can react with a second peptide with a C-terminal α-thioester
to form a peptide bond (Figure 8a)145,146. The fusion of a recombinant protein α-thioester
with a synthetic N-terminal cysteine peptide was accomplished by re-engineering the
process of protein splicing. In protein splicing, a protein segment termed an intein is
excised out of two flanking sequences, named exteins, in a process analogous to the
splicing of RNA introns (Figure 8b)147. This fascinating autocatalytic process has been
exploited for many different purposes by our group and others. However, one of the
simplest uses of protein splicing has proven to be the most versatile: by mutating the
intein to prevent the formation or breakdown of the branched intermediate, the protein
can be trapped in equilibrium between the α-thioester and amide forms. The mutated
intein can then be cleaved by treatment with thiols, generating a recombinant protein αthioester. The ligation of the recombinant protein α-thioester with a synthetic N-terminal
cysteine peptide was first reported in 1998 (Figure 8c)148-150, and has been termed
expressed protein ligation (EPL) or, less frequently, intein-mediated protein ligation.
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Figure 8. Mechanism of native chemical ligation (NCL) (a). In NCL, transthioesterification by the N-terminal cysteine is followed by an S->N acyl shift, generating
a native peptide bond. Mechanism of protein splicing (b). In protein splicing, an N -> S
or O acyl shift at the N-terminal residue of the intein is followed by trans(thio)esterification to the residue C-terminal to the intein, generating a branched intermediate.
The C-terminal Asn of the intein then cleaves the C-terminal intein-extein bond,
generating a succinimide product, and the fused exteins undergo an (S,O)-> N acyl shift
to create a native peptide bond. Mechanism of EPL (c). In EPL, a thiol is used to generate
a α-thioester from a mutated intein. The α-thioester can then react by NCL with an Nterminal cysteine peptide. R = alkyl, phenyl, benzyl, CH2CH2SO3Na. X = O, S.

Heterologous expression of leptin in E. coli generally requires isolation from
inclusion bodies151. Thus, in order to generate an active intein fusion protein, we fused
leptin to the GyrA intein, which can be refolded from bacterial inclusion bodies using
conditions previously developed in our laboratory152. Unfortunately, these refolding
conditions resulted in precipitation of the leptin-GyrA fusion. Thus, we tested the ability
of the intein to cleave in the presence of various additives, including detergents, small
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molecule additives, and chaotropes. We found that 4M urea was most effective in
promoting the cleavage of the intein (Figure 9). Upon refolding in 4M urea, intein
cleavage with sodium-2-mercaptoethanesulfonate allowed the preparation of the
corresponding α-thioester (Figure 10). Following EPL of the α-thioester with cysteine to
reconstitute full-length leptin (Figure 11a), and refolding to form the disulfide bond
between Cys97 and Cys147 using reduced and oxidized glutathione as a redox couple,
leptin with activity identical to recombinant commercial leptin could be produced (Figure
11b). These optimized protocols were subsequently applied to the generation of a site
specifically 18F labeled protein (see section 2.4).
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Figure 9. Optimization of leptin intein-cleavage conditions. Leptin-GyrA-His6 was
refolded into pH 7 buffer containing the indicated additives and cleaved with 3%
ethanethiol overnight at room temperature (RT) or 4° C (NT= no thiol).
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Figure 10. A) Expression and purification of leptin α-thioester 1. Coomassie stained 420% gradient SDS-PAGE analysis of leptin purification fractions. A: Crude insoluble
fraction from cell lysate. B: Leptin-GyrA-His6 purified on a Ni-NTA column. C:
Cleavage of leptin-GyrA-His6 using 100 mM MESNa. D: Eluate of leptin α-thioester 1
from the Ni-NTA column, E: Purified leptin α-thioester 1. B) ESI-MS of leptin-MESNa
α-thioester 1 (calculated mass 16156.2 Da, obtained 16157.2 ± 3.0 Da). Charge states are
indicated. The smaller peaks represent the hydrolyzed thioester.
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Figure 11. A) ESI-MS reconstruct of murine leptin produced in an EPL protocol
(calculated mass 16135.6, obtained 16134.6 ± 2.5). B) Leptin receptor-STAT3 dependant
luciferase assay comparing the activity of recombinant leptin produced by an EPL
protocol and recombinant leptin obtained from a commercial source. EC50 for
recombinant leptin = 0.49 nM (95% confidence intervals 0.39-0.61 nM). EC50 for
semisynthetic leptin = 0.31 nM (95% confidence intervals 0.25-0.38 nM)
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2.4 Synthesis of 18F-FBA-leptin
As mentioned above (see section 1.7, 2.1), several methods for protein labeling
with the isotope 18F have been described. While a one step radiochemical labeling
strategy, in which aqueous 18F could be directly appended to leptin, would be optimal,
current methods are not applicable to protein labeling due to the very low specific activity
of the resulting products108, or the requirement for organic solvents109. Thus, a two-step
methodology was required. We were attracted to the use of 18F-4-fluorobenzaldehyde
(FBA), owing to its previous use in chemoselective ligations with synthetic peptides114.
We rationalized that leptin could be radiolabeled using this synthon, if the protein were
labeled site-specifically with an aminooxy functional group. Thus, we developed an EPL
strategy for labeling leptin site-specifically at its C-terminus with an aminooxy functional
group for the purpose of site-specific oximation with 18F-FBA. Again, this strategy
exploits the fact that leptin has a cysteine at its N-terminus, allowing for the facile
incorporation of modifications using EPL.
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Scheme 2: Synthesis of 18F-FBA-leptin 5. Reaction conditions: a) 100 mM
mercaptoethanesulfonic acid, 4M urea, 150 mM NaCl, 100 mM sodium phosphate pH
7.0, 4 °C, 2 days. b) 20 mg/mL 1, 10 mg/mL 2, 100 mM mercaptoethanesulfonic acid,
6M Gn-HCl, 150 mM NaCl, pH 7.2, 1 day. c) Refolding by stepwise dialysis and
disulfide exchange. d) 20 mg kryptofix, 2 mg potassium carbonate, 1-2 mg (4formylphenyl)trimethylammonium trifluoromethanesulfonate and K18F in DMSO, 120
°C, 8 minutes. e) 30 nmol 4, 100 mM anilinium acetate pH 4.5, 15 minutes, 0° C.

An overview of the synthetic strategy to generate 18F-FBA-leptin is depicted on
Scheme 2. Leptin α-thioester 1 was prepared as described in section 2.3 and ligated to
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cysteine derivative 2 to give leptin analog 3 (Scheme 2). Compound 2 was synthesized by
solid phase methods and contains two reactive moieties, namely a cysteine and an
aminooxy group, separated by a short PEG spacer (Scheme 3, Figure 12). In preliminary
studies, we found the PEG spacer was required to maintain native-like solubility of the
final folded product. We anticipated that at pH 7 the α-thioester in protein 1 would react
preferentially with the cysteinyl group in 2, via native chemical ligation, due to the
relatively slow rates of hydroxymate formation under these conditions153,154. The EPL
reaction between 1 and 2 was complete after 24 hours at which point the crude ligation
mixture was refolded as described above. The refolded aminooxy-leptin analog 4 was
then purified by RP-HPLC (Figure 13a, b). Aminooxy-leptin analog 4 gave an identical
tryptic digestion pattern to commercially available recombinant leptin as determined by
LCMS (Figure 13c). As expected for natively folded leptin, the two C-terminal tryptic
peptides in 4 were found to be linked by a disulfide bond, while no reduced tryptic
peptides could be found. Interestingly, the mass spectrum of this disulfide-linked Cterminal tryptic peptide contained a peak of mass consistent with loss of aminooxyacetate. The presence of this fragment, which may have been produced either by
trypsinolysis of the aminooxyacetate, or by gas phase fragmentation, provides evidence
that protein 4 contains the desired amide bond at the ligation site, since aminooxy-acetate
could not be lost from a hydroxymate-containing ligation side-product.
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Figure 12. A) C18 analytical RP-HPLC chromatogram of purified peptide 2 on a 5-20%
B gradient. B) ESI-MS of peptide 2 (calculated mass 639.8 Da, obtained [M+H]+ = 641.0
Da).
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Figure 13. Synthesis and characterization of AOA-leptin 4. a) RP-HPLC chromatogram
of 4 on a 0-100% B gradient on a C4 analytical column. b) ESI-MS reconstruct of AOAleptin 4 (calculated mass 16652.2 Da, obtained 16652.2 ± 3.3 Da). c) Trypsinization
HPLC/MS analysis of commercial recombinant leptin (black) and AOA leptin 4 (red).
The indicated peaks connected by a line were identified as the corresponding tryptic
peptides by ESI-MS. The disulfide bond between C97 and C147 is indicated.
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Cold FBA-leptin derivative 5 was generated by overnight treatment of 4 with 1
mM 4-fluorobenzaldehyde at 4 °C in 100 mM sodium acetate buffer, pH 4.5. No side
reactions were detected, and the resulting oxime-containing product was purified by RPHPLC and the identity confirmed by ESI-MS (Figure 14a). FBA-leptin 5 was then tested
for its ability to activate leptin receptor signaling using the aforementioned ObRbSTAT3-luciferase assay (Figure 6). In this assay, 5 induced leptin receptor signaling to a
similar extent as commercial recombinant leptin, with a slightly increased EC50 (95%
confidence intervals 0.26-0.34 nM for recombinant leptin and 1.0-2.0 nM for 5, Figure
14b). This subtle reduction in potency observed for 5 was not due to the ligation or
refolding procedures employed in its preparation as unmodified leptin generated via a
similar EPL procedure had an identical EC50 compared to commercial recombinant leptin
in this assay (Figure 11b). Importantly, when administered to ob/ob mice via
subcutaneous osmotic pumps, FBA-leptin 5 had identical ability to induce weight loss
over a 24 hour period as commercial recombinant leptin (Figure 14c). We conclude that
FBA-leptin 5 is able to bind and activate the leptin receptor, and that it is able to induce
weight loss in mice, the hallmark of leptin bioactivity.
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Figure 14. Characterization and biological activity of FBA-leptin 5. a) ESI-MS
reconstruct of FBA-leptin 5 (calculated MS 16758.3, obtained 16760.9 ± 3.5). b) ObRSTAT3 dependant luciferase assay comparing the activity of FBA-leptin 5 (blue
triangles) and recombinant leptin (red squares), n = 2 ± s.d.. c) Comparison of the weight
loss induced by FBA-leptin 5, recombinant leptin, and PBS vehicle in ob/ob mice.
Samples were infused at a constant rate of 450 ng/hr. The weight of the animals was
recorded after 24 hours (n = 4 ± s.e.m).
Synthesis of 18F-FBA was accomplished as previously described155, with minor
modifications, using the precursor (4-formylphenyl)trimethylammonium
trifluoromethanesulfonate. Initial attempts towards oximation of 18F-FBA with leptin
analog 4 failed owing to precipitation of the protein at elevated temperatures required to
allow the reaction to proceed in good yield114,115. Jencks and co-workers described
catalysis of semicarbazone formation between 4-chlorobenzaldehyde and semicarbazide
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by aniline and substituted derivatives thereof, and recently Dawson and co-workers found
that aniline acts as a catalyst in peptide oxime ligations156,157. Thus, we reasoned that
aniline should catalyze the radiochemical oximation of 18F-FBA with aminooxy-leptin 4.
Comparison of the rate of oximation of aminooxy-leptin 4 in 100 mM sodium acetate or
anilinium acetate at 4 °C revealed that aniline dramatically accelerates the reaction
(Figure 15a). Notably, aniline catalysis allows the reaction to proceed in good yield at
lower concentration of the aminooxy precursor, and at lower temperature than previously
described for this radiolabeling reaction114,115.
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Figure 15. Catalysis of radiochemical oximation of AOA-leptin 4 with 18F-FBA by
aniline and characterization of the 18F-FBA-leptin 5. a) Catalysis of the oximation
reaction by aniline. 125 uM 4 was incubated with 18F-FBA in the presence of either 100
mM sodium acetate pH 4.5 (triangles) or 100 mM anilinium acetate (diamonds) at pH 4.5
on ice. The radiochemical yield was quantified by TLC and confirmed by RP-HPLC. The
results are an average ± standard deviation of four experiments. b) Radiochemical HPLC
of 18F-FBA-leptin 5, on a C4 analytical column. c) 18FBA-leptin 5 was incubated with a
cell line overexpressing ObRb in the presence or absence of 5 μM competing leptin
(average of 2 experiments).
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Scheme 4. Overview of method to label aminooxy-leptin 4 with 18F-FBA.

The method for preparative-scale labeling of aminooxy-leptin 4 with 18F-FBA is
depicted on Scheme 4. Preparative scale 18F labeling of aminooxy-leptin 4 was
accomplished by treatment with 18F-FBA in 100 mM anilinium acetate on ice for 15
minutes, and purification of the resulting mixture on a P-6 gel filtration column. Using
this method, 74-185 MBq (2.5-5.0 mCi) of 18F-FBA-leptin 5 could be recovered starting
from 7.4-11.1 GBq of 18F, with a total synthesis time of ~120 minutes (n=4). The specific
activity of the protein varied from 9.25-16.65 GBq/μmol, and the radiochemical purity of
the protein was greater than 95% as judged by iTLC and HPLC (Figure 15b). The ability
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of 18F-FBA-leptin 5 to bind to the aforementioned cell line expressing ObRb was tested.
We found that the labeled protein bound to the cells when incubated together at room
temperature, and that binding could be blocked by the addition of an excess of
unmodified recombinant leptin (Figure 15c). Additionally, the presence of the toxic
catalyst aniline could not be detected in the final preparation of leptin by RP-HPLC.
The stability of the 18F-FBA-leptin 5 was tested both in vitro and in vivo. Over the
course of an hour, the protein was stable in PBS (10 mM sodium phosphate, 140 mM
sodium chloride, pH 7.4), 100 mM sodium acetate, pH 4.5, and mouse serum in vitro as
determined by HPLC analysis (Figure 16b-d). Finally, the stability was tested in vivo. In
blood recovered from mice, greater than 95% of the radioactivity detected corresponded
to intact 18F-FBA-leptin 5 (Figure 16a). Thus, the stability of the protein is sufficient for
studies both in vitro and in vivo. Importantly, this synthesis provides sufficient highly
stable radiolabeled protein in good specific activity for studies in small and large animals,
as well as in humans, with the biological activity of the protein intact.
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Figure 16. Stability of 18F-FBA-leptin 5 in vivo and in various buffers. a) Radiochemical
RP-HPLC of serum recovered from wild type mice injected with 18F-FBA-leptin 5 30
minutes prior. Similar results were obtained from ob/ob mice. b-d) Radiochemical HPLC
of 18F-FBA-leptin after incubation for 60 minutes in PBS, 100 mM sodium acetate pH
4.5, or mouse serum, respectively. Stability in PBS and sodium acetate was greater than
95% while in serum it was 93% stable. The initial purity of the labeled product in this
experiment was 96%.

We next performed preliminary PET imaging experiments in mice. 18F-FBAleptin 5 (3.7-5.55 MBq) was injected in ob/ob mice, and they were immediately imaged
in a micro-PET scanner. We found that most of the protein rapidly accumulated in the
kidneys (Figure 17a) in agreement with previous biodistribution studies84,96,158. A key
advantage of 18F over other nuclides is the improved resolution of the PET images
obtained, up to five fold101. To illustrate this, we compared images obtained using 68Ga-
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DOTA-leptin against those obtained with 18F-FBA-leptin. As expected, the resolution of
the micro-PET images obtained with 18F-FBA-leptin was substantially improved over
images produced with 68Ga-DOTA-leptin. Thus, while imaging 68Ga-DOTA-leptin
demonstrated binding to the kidney in mice (Figure 17b), imaging using 18F-FBA-leptin 5
clearly reveals binding specifically in the cortex of the kidney, with less binding in other
regions (Figure 17a). This pattern is consistent with the uptake of the hormone in the
cortex of the kidney, in agreement with previous results50.
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Figure 17. a) Serial coronal PET images of ob/ob mouse kidneys, injected with 68GaDOTA-leptin. b) Serial coronal PET images of ob/ob mouse kidneys, injected with 18FFBA-leptin 5.

51

2.5 Toward 18F-labeling of lysine residues using aminooxyacetic acid-modified side
chains
One alternative approach to 18F-labeling of leptin would be to adopt a lysine sidechain modification technique, similar to the DOTA modification method (Section 2.2).
Lysine directed side-chain modification using 18F has been previously described using
18F-fluorobenzoic acid, succinimide ester (FSB), and applied to a variety of
substrates122,159. Similarly, Chang et al. labeled the side chains of albumin with
hydrazinonicotinic acid, succinimide ester, and subsequently conjugated 18F-FBA to
generate a hydrazone product125. We were attracted to the latter technique, owing to our
experience with 18F-FBA, and the finding that aniline catalyzes reactions of this
type156,157,160. However, we were concerned that the stability of a hydrazone containing
conjugate would be insufficient for the study of leptin biodistribution of leptin in vivo,
based on previous reports revealing degradation of 18F-FBA labeled hydrazone
conjugates in mildly acidic solution118. Although, to our knowledge no direct comparison
has been made between the stability of oxime and hydrazone conjugates in vivo, a recent
model study revealed greater stability of oximes as compared to hydrazones in aqueous
buffers161. Thus, we envisioned a leptin labeling approach in which aminooxy groups
could be installed on lysine side chains, which could be subsequently derivitized with 18FFBA, to generate the stable oxime linkage.
A method to generate aminooxy-derivitized proteins by native chemical ligation
was developed by Shao et al., who found that 1M methoxylamine could be used to
deprotect an isopropylidene protecting group on an aminooxyacetic acid moiety in the
context of a small protein, CCL-5 (RANTES)162. Thus, we devised a synthetic strategy in
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which the lysine side chains and N-terminus of leptin could be modified using
isopropylidene-aminooxyacetic acid, succinimide ester (6), deprotected using
methoxylamine, and finally labeled with 18F-FBA (Figure 18). We synthesized 6 using
the method depicted on Figure 19a in two steps in 52% overall yield. We then conjugated
the reagent to leptin. Similar to leptin labeling with DOTA-NHS, we found that the
stoichiometry of 6 to leptin determined the degree of leptin labeling (Figure 19b).
Importantly, treatment with 500 mM methoxylamine on ice overnight removed all of the
isopropylidene protecting groups following conjugation with 6 in a one pot reaction, in
70% yield (Figure 19c, d). In preliminary experiments, we found that this aminooxyleptin derivative could be labeled with 18F-FBA, in similar yield to aminooxy-leptin 4
(data not shown). Thus, this technique allows for lysine side-chain modification of
proteins with aminooxyacetic acid, and is a promising technique for generating 18Flabeled protein tracers.

Figure 18. Schematic of lysine chain modification strategy to generate aminooxy leptin.
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Figure 19. Preparation of aminooxy-leptin by modification of lysine side chains. A)
Synthetic scheme to generate isopropylidene-aminooxyacetic acid-ONHS (6). B) RPHPLC of leptin labeled with 6, on the same 0-100% B gradient on a C4 analytical
column. Four equivalents were used for the red trace, and 20 for the blue trace. The
number of equivalents of 6 per leptin molecule is indicated above each HPLC peak. C)
HPLC of deprotected aminooxyacetic acid-leptin following the conjugation with four
equivalents of 6 (i.e. the red trace from B). D) ESI-MS of the product of the deprotection
reaction (i.e. the starred peak from panel C) The number of amionooxyacetic acid labels
per leptin molecule is indicated.
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2.6 Summary of tracer development
In conclusion, we have developed two complementary radiolabeled tracers, which
we term 68Ga-DOTA-leptin, and 18F-FBA-leptin. DOTA labeling of leptin was
accomplished in an amine directed manner using DOTA-NHS, incorporating an average
of 4 chelators per protein molecule (fig 7b). DOTA-leptin could readily be labeled with
68

Ga in good yield. A site-specific 18F-labeling strategy was developed, in which an

aminooxy functional group was first installed on the C-terminus of leptin using EPL,
which was subsequently derivitized in an aniline accelerated oximation reaction with 18FFBA (Scheme 2)163. Thus, the 18F labeling method we have developed is intrinsically sitespecific, and should be readily applicable to other substrates. Furthermore, both tracers
preserve the ability to bind to and activate ObRb and induce STAT3 signaling, and to
induce weight loss in ob mice. A comparison of the imaging properties of the two tracers
revealed that 18F-FBA-leptin has higher resolution compared to 68Ga-DOTA-leptin,
allowing for the uptake of the tracer in the cortex of the kidney to be visualized (Figure
17). Additionally, a lysine directed labeling strategy to generate 18F-FBA-modified leptin,
based on the conjugation of aminooxyacetic acid to lysine side chains, was developed.
The use of these tracers to interrogate leptin biology in model systems in rodents and
primates is discussed in chapters 3 & 4, and an extensive comparison of our tracers to
others in the literature is presented in section 5.1.
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Chapter 3. Imaging leptin biodistribution by PET reveals clearance of the hormone
by Megalin in the cortex of the kidney

The work described in this chapter was performed in close collaboration with G.
Ceccarini (Friedman lab)

Section 3.1. Leptin half life, clearance, and biodistribution.
Leptin is a 16 kDa protein hormone, produced and secreted into the circulation by
adipocytes, which regulates body weight homeostasis by reducing food intake and
increasing energy expenditure19,24. Leptin also signals nutritional status to several other
physiological systems and modulates their function. Plasma leptin levels are directly
proportional to the amount of adipose tissue mass13, and its major site of action is in the
hypothalamus, where it binds and activates the leptin receptor (ObR). In addition, a
number of non-ObR binding partners interacting with leptin have been identified, but
their physiological significance is unknown44,45,49,50. Leptin action in the central nervous
system is both necessary18 and sufficient52 to generate many of the effects of the hormone.
Additionally, the hormone has direct effects on some peripheral tissues, modulating their
function (see section 1.3)62,64,67,75. In particular, leptin has a short half-life which follows
biphasic kinetics84-87. All available evidence suggests that leptin is cleared by the kidney,
as would be expected based on its small size84,87,89-91,158,164,165. However, the molecular
mechanism underlying this uptake remains unclear. The kidney expresses both ObR and
the multiligand endocytic receptor megalin50,166,167. Recently, leptin was found to bind to
an L2 yolk sac tumor cell line expressing megalin. Furthermore, purified megalin binds
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to leptin with an apparent Kd of 200 nM as revealed by quartz crystal microbalance
(QCM) analysis50, a technique analogous to surface plasmon resonance which allows the
monitoring of protein-protein interactions on surfaces168. Thus, both megalin and ObR are
candidate receptors for leptin uptake in the kidney.
In vivo imaging of leptin biodistribution could be used to characterize the
molecular mechanism of leptin uptake in various organs in animal models. Positron
emission tomography (PET) is well suited for this purpose due to mm scale resolution,
high sensitivity, and ease of quantification112. Furthermore, by using the appropriate
genetically modified animals, the role of various receptors in regulating biodistribution
can be determined. Herein we describe the application of two tracers, 18F-FBA-leptin163
and 68Ga-DOTA-leptin (see chapter 2), to micro-PET imaging in various rodent and
primate models. We found that leptin was rapidly taken up in a saturable manner in the
kidney, and that this uptake was dependant on the multiligand endocytic receptor
megalin.

Section 3.2 Whole body PET scans in rodents and rhesus macaques using 18F-FBAleptin and 68Ga-DOTA-leptin
Firstly, we analyzed the biodistribution of leptin in normal mice and rats. In
Figure 20a we show a typical whole body image of a leptin deficient (ob/ob) mouse
injected with

68

Ga-DOTA-leptin, imaged by micro-PET for an hour. The tracer

accumulates principally in the kidneys, but also in other visceral organs such as liver and
spleen, and in the head. The tracer was largely absent from fat and brain. The low level of
uptake in the bladder (2.2% of total injected dose) likely represents
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68

Ga-DTPA, an

impurity of the radiochemical synthesis, which is known to be rapidly cleared to the
urine169. Similar results were obtained with the 18F-FBA-leptin tracer as shown in Figure
20b. The improved anatomical definition of 18F compared to 68Ga allowed us to observe
the specific accumulation of the tracer in the periphery of the kidney (cortex) rather than
the inner portion of the organ (medulla, Figures 18, 19b, e). This finding was confirmed
using the 68Ga-DOTA-leptin tracer in a rat model, where the larger size of the animal
permits visualization of the cortex, despite the lower resolution of the

68

Ga isotope

(Figure 20c). Uptake in the proximal femur was also observed in the rat images,
suggesting uptake in bone marrow. To test if a similar biodistribution pattern could be
also observed in primates, we imaged rhesus macaques using

68

Ga-DOTA-leptin as a

tracer. The high definition of the PET-CT scan confirmed the renal cortical uptake of the
tracer (Fig 19d). The fact that both 68Ga-DOTA-leptin and 18F-FBA-leptin provide similar
images, that these patterns of distribution are consistent with previous biodistribution
studies92,96, and are consistent between species, strongly suggests that the pattern of
radioactivity observed in these images coincides with the authentic biodistribution of
leptin.
Urine formation occurs in the renal tubules, which travel from the cortex of the
kidney (proximal convoluted tubules) deep into the medulla (loop of Henle), and return to
the cortex (distal convoluted tubules, Figure 20e, f). A previous study, in which 125I leptin
was injected into mice, and the biodistribution subsequently analyzed ex-vivo by
autoradiography, suggested that leptin is taken up in the proximal convoluted tubule50.
Taken together with these previous results, our data suggest that leptin is taken up by the
proximal convoluted tubule within the cortex of the kidney.
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Figure 20. Whole body PET images of mice, rats, and rhesus macaques reveal that leptin
is taken up in the cortex of the kidney in mammals. The images are overexposed to reveal
areas with a lower level of uptake. a) Whole body PET maximum intensity projection
(MIP) image of a leptin deficient (ob/ob) mouse injected with 68Ga-DOTA-leptin. Renal
uptake of leptin in ob/ob mice is 65.1% ± 3.5% while the bladder is only 2.2 ± 0.2% over
30 min. Uptake in other organs is lower than this per volume. b) Whole body PET
coronal MIP image of an ob/ob mouse injected with 18F-FBA-leptin, with inset of kidneys
with lowered contrast, revealing uptake of the hormone in the cortex of the kidney. c)
Whole body PET coronal MIP of a Sprague-Dawley rat injected with 18F-FBA-leptin,
with inset with lowered contrast, revealing uptake of the hormone in the cortex of the
kidney. d) Coronal section of a PET-CT fusion image of a rhesus monkey injected with
68
Ga-DOTA-leptin, revealing uptake of the hormone in the cortex of the kidney e, f)
Simplified diagram of kidney and renal tubular anatomy.
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Section 3.3. Quantitative analysis of renal uptake of leptin
One of the strengths of PET imaging is quantitative kinetic analysis of uptake in
organs. We therefore generated time vs. activity curves in the kidney and bladder by
drawing regions of interest on the aforementioned anatomical regions of the micro-PET
images. First, we compared the performance of our two tracers. We found that 18F-FBAleptin accumulated rapidly in the kidneys, but then the kidney radioactivity began to
decrease and move to the bladder as time progressed (Figure 21a). In contrast,

68

Ga-

DOTA-leptin uptake increased continually in the kidney over the course of the scan,
while the level in the bladder remained consistently low (Figure 21a). Radiochemical
HPLC analysis of the urine of the 18F-FBA-leptin injected animals revealed that the tracer
had been metabolized to uncharacterized byproducts (Figure 21b). Since 18F-FBA-leptin
is stable in serum in vitro, and in vivo (Figure 16a, c), this metabolite is probably formed
following endocytosis of leptin by proximal convoluted tubule cells, where it diffuses out
into the urine. It is interesting to note that a similar phenomenon was observed in the
hepatobiliary clearance of 18F-FBA labeled LDL particles128. Previous analysis of

111

In-

DOTA labeled antibody fragments has demonstrated that the final product of intracellular
metabolism is 111In-DOTA-lysine, which is retained in lysosomes170. Thus, it is likely that
68

Ga-DOTA-leptin is similarly degraded to

68

Ga-DOTA-lysine. Tracers which are

retained intracellularly following degradation are termed “residualizing tracers171.” Thus,
we used

68

Ga-DOTA-leptin for all further quantitative analysis, as the fact that it is

residualizing tracer allows for the accurate quantitation of tissue uptake.
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Figure 21. 68Ga-DOTA-leptin is a residualizing tracer, while 18F-FBA-leptin is not. A)
Representative time activity curves of organ uptake of 68Ga-DOTA-leptin and 18F-FBA
leptin in mouse kidneys and urinary tract. Organ uptake is defined as the total activity
quantified in an organ, divided by total body radioactivity, with both quantified by region
of interest (ROI) analysis of PET scans. B) Radiochemical HPLC analysis of urine from a
mouse injected with 18F-FBA-leptin indicating degradation of the tracer after one hour.
For reference HPLCs of intact 18F-FBA-leptin on the same gradient see figures 15b, 16.
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Three wild type C57BL/6J mice were scanned after injection of

68

Ga-DOTA-

leptin, and quantification of kidney and bladder uptake on the resulting micro-PET
images revealed that 68.2 ± 1.5% and 3.1% ± 0.6% of the tracer was taken up over 30
minutes, respectively (Figure 22a, e). Radiochemical HPLC analysis of kidney extracts
isolated from mice, which had been injected with the tracer, revealed only a peak at 3
min, indicating that the leptin had been degraded at later time points (presumably to 68GaDOTA-lysine, see above). When co-injected with a 30 fold excess of cold ligand, 23.7 ±
2.2% of the leptin was displaced from the kidney to the bladder, with 47.3 ± 2.0%
retained in the kidney (Figure 22c, e). Radiochemical HPLC analysis of the urine of these
animals revealed a peak at 21.6 min, the characteristic retention time of leptin on this
gradient, indicating that intact leptin is displaced from the kidney receptors (Figure 22d).
Thus, micro-PET imaging of

68

Ga-DOTA-leptin biodistribution in mice reveals the

presence of a saturable uptake system in the cortex of the kidney.
We then confirmed these results using ex-vivo biodistribution analysis. In these
experiments, a radiotracer is injected (in this case 68Ga-DOTA-leptin or commercially
available

125

I-leptin), and following a period of time, the animals are sacrificed, and the

radioactivity in the corresponding tissues counted. Thus, these experiments are analogous
to PET imaging experiments, with only one time point - when the animal is sacrificed.
The advantage of this technique is that a smaller radioactive dose need be injected to
quantify tissue uptake (under 10 ng vs. 20 µg in a PET experiment), potentially
minimizing effects of receptor saturation. In contrast to PET imaging experiments, the
addition of competing cold leptin increases the amount of protein accumulating in the
kidney in this analysis (Figure 23a). This is probably due to the fact that peripheral
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receptors only become saturated when cold leptin is co-injected. When peripheral
receptors are saturated, a much higher level of protein is delivered to the kidney, probably
explaining the paradoxical increase seen in Figure 23a. A similar phenomenon was
observed in PET imaging experiments in rhesus macaques (see section 4.4, Table 4,
Figure 34). In order to exclude the contribution of increased protein delivery to the
kidney resulting from saturation of peripheral ObR, we present the biodistribution on
Figures 22b and c as a ratio of (urinary leptin / kidney leptin + urinary leptin). This
analysis excludes the contribution of increased delivery of leptin to the kidney via the
bloodstream, and instead quantifies only binding within the tubules of the kidney. When
analyzed in this manner, biodistribution experiments performed ex-vivo using
DOTA-leptin and

125

68

Ga-

I-leptin similarly confirmed that kidney binding can be partially

displaced to the urine (Figure 23b, c). These results mimic the pattern observed via PET
imaging. Therefore, uptake of leptin in the tubules of the kidney is partially saturable in
rodents, as revealed by both PET imaging and biodistribution analysis.
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Figure 22. Leptin uptake in the kidney is partially saturable in mice as detected by PET imaging.
a) Coronal maximum intensity projection (MIP) of a C57Bl6 wild type mouse injected with
68
Ga-DOTA-leptin, with inset of radiochemical HPLC analysis (b) of homogenized kidneys one
hour post injection with 68Ga-DOTA-leptin c) Coronal MIP of a C57Bl6 wild type mouse coinjected with 68Ga-DOTA-leptin and 650 µg leptin, with inset of a radiochemical HPLC analysis
of the urine 30 minutes post injection (d). e) Time activity curves of the kidney of C57Bl6 wild
type mice injected with 68Ga-DOTA-leptin in the presence or absence of 650 µg leptin. Kidney
uptake on the Y-axis is defined as the total radioactivity quantified in the kidney, divided by total
body radioactivity, with both quantified by region of interest (ROI) analysis. All data are
reported as means (n=3) ± s.e.m. Statistical significance of the difference between the two
groups was assessed by Student’s T-test, p< 0.01.
64

Figure 23. Ex-vivo biodistribution analysis reveals saturable uptake in the kidneys of ob
and wild type mice. A) Ex vivo biodistribution analysis of 125I leptin in wild type and
ob/ob mice reveals an increase in accumulation of leptin in the kidney when coinjected
with cold leptin. B, C) Ex vivo biodistribution results of 125I-leptin (B) or 68Ga-DOTAleptin (C) in ob/ob and wild type C57Bl6 mice. The fraction of radioactivity appearing in
the urine divided by the activity in the kidney plus urine is represented on the Y-axis. n=
2-3 ± S.E.M.
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Section 3.4. Comparison of kidney uptake of leptin in ob/ob and ObRΔ/ob/ob mice
In order to test if the ObR is required for the uptake of leptin in the kidney, we
compared wild type mice, leptin deficient (ob/ob) and leptin/leptin receptor deficient
mice (ObRΔ/ob/ob). ObRΔ/ob/ob mice have a functional knock out for all the isoforms
of ObRs and are also leptin deficient. This model allows us to dissect the role of ObRs
without the potential confounding factor of elevated leptin levels associated with the
receptor deletion. Results from ObRΔ/ob/ob can therefore be directly compared to those
obtained in ob/ob littermates. Time activity curves, obtained by ROI analysis of PET
images of renal uptake in the three experimental groups are superimposable, suggesting
either that ObR mediated uptake is saturated in this model, or that ObR mediated uptake
is very low in this organ (Figure 24a).
In order to exclude the possibility that saturation of ObR is responsible for the
identical levels of uptake in the kidney in PET imaging, biodistribution experiments were
performed in the same animal strains using

125

I-leptin. In this assay, substantially less

leptin accumulates in the kidneys, owing to the fact that there is no saturation of ObR
dependant binding sites, as is the case in micro-PET imaging experiments (e.g. compare
Figure 24a, b). There is no statistically significant difference in the uptake of 125I-leptin in
the kidney in wild type, ob/ob, and ObRΔ/ob/ob mice as assayed by ex vivo
biodistribution analysis (Figure 24b). However, when corrected for the slightly higher
blood levels of 125I-leptin in ObRΔ/ob/ob mice (see chapter 4 for a full discussion of this
analysis), there is a trend of reduced uptake in the kidneys of ObRΔ/ob/ob vs ob/ob mice
(Figure 24c, not statistically significant by Student’s one-tailed t test, p value of 0.054).
This suggests that there may be a low level of ObR mediated uptake in the kidneys of
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mice, which is less than that mediated by other mechanisms. However, ObR mRNA
could not be detected in the kidney in rhesus macaques by northern blotting172, suggesting
that ObR could not be involved in the uptake of leptin of the kidney in rhesus macaques.
Taken together, our data indicate that ObR mediated uptake is insufficient to account for
the very high level of uptake of leptin in the kidney, and another mechanism must
underlie this phenomenon.
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Figure 24. ObR does not mediate the majority of leptin uptake in the kidney. A) A
comparison of the uptake of 68Ga-DOTA-leptin in the kidneys of wild type C57Bl6,
ob/ob, and ObRΔ/ob/ob mice as judged by micro-PET imaging. Kidney uptake on the Yaxis is defined as the total radioactivity in the kidney, divided by total body radioactivity,
with both quantified by region of interest (ROI) analysis. B) A comparison of the uptake
of 125I-leptin in the kidneys of wild type C57Bl6, ob/ob, and ObRΔ/ob/ob mice as judged
by biodistribution analysis. Kidney uptake on the Y-axis is defined as the total
radioactivity quantified in the kidney, divided by total body radioactivity (n = 3-4 ±
s.e.m.) C) A comparison of the uptake of 125I-leptin in the kidneys of wild type C57Bl6,
ob/ob, and ObRΔ/ob/ob mice as judged by biodistribution analysis, following correction
for blood radioactivity. Kidney uptake on the Y-axis is a dimensionless variable, defined
as the total radioactivity quantified in the kidney divided by the mass of the kidney,
divided by the fraction of injected dose per gram of blood (i.e., the standard uptake value
of leptin in the kidney when compared against the reference of radioactivity in the blood,
n = 3-4 ± s.e.m).
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Section 3.5 Quantitative analysis of renal uptake and metabolism of leptin in
megalin knockout mice
We then tested the role of megalin (gp330/LRP2) in the kidney uptake of leptin.
Megalin is a 600 kDa type I glycoprotein receptor, which is expressed is various tissues
in mammals including the proximal convoluted tubule of the kidney, the choroid plexus,
and other sites167. Megalin has a similar domain organization to the LDL receptor, with an
extracellular domain consisting of four clusters of cysteine rich LDL receptor type A
repeats, which are believed to mediate ligand binding, separated by seventeen EGF-type
repeats each. Megalin is known to bind to a variety of ligands, including albumin,
apolipoproteins, various vitamin and hormone carrying proteins such as thyroglobulin
and vitamin-D binding protein, and low molecular weight hormones such as insulin,
prolactin, and parathyroid hormone, and mediate their clearance in the proximal
convoluted tubule of the kidney166,167. Leptin had been previously shown to be
endocytosed and degraded by the yolk sac L2 tumor cell line (which expresses
megalin173) and to bind to megalin in vitro using QCM analysis50. Additionally,
antibodies against megalin were able to co-immunoprecipitate exogenously added leptin
from a choroid plexus cell line, and siRNA directed against megalin reduced uptake of
leptin into the brain in mice174. Taken together, these results suggest that leptin binds to
megalin in L2 and choroid plexus cells. Furthermore, these studies suggest the hypothesis
that leptin clearance may be mediated by megalin in the proximal convoluted tubule of
the kidney, and that leptin transport into the CSF may be mediated by megalin.
In order to test if megalin was responsible for the kidney uptake of leptin in vivo,
we obtained mice with a kidney specific gene deletion of the receptor megalin (termed
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megalinlox/lox, ApoEcre, kind gift of T. Willnow, Max-Delbrueck-Center for Molecular
Medicine, Berlin)175. In this model, cre recombinase expression in the kidney is driven by
a fragment of the human apolipoprotein promoter E (apoE) and megalin expression is
reduced to 10% of normal levels175. We measured leptin levels in urine of megalinlox/lox,
ApoEcre mice by an Enzyme-Linked ImmunoSorbent Assay (ELISA). Leptin levels are
undetectable in the urine of rodents158 but in megalinlox/lox, ApoEcre mice levels are 16.7 ±
2.9 ng/mL (SEM, n=4) indicating a significant leptin loss in urine (Figure 25a). In the
urine of the megalinlox/lox, ApoEcre mice, leptin is intact as confirmed by western blotting
(Figure 25b). These results strongly suggest that megalin is required for the reuptake of
leptin in the proximal convoluted tubule of the kidney.
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Figure 25. Leptin is released intact in the urine of Megalinlox/loxApoECre mice. A)
Enzyme-Linked ImmunoSorbent Assay (ELISA) of leptin in the urine of the indicated
mouse strains. The dotted line represents the limit of detection (n=3 ± s.e.m., statistical
significance of difference between Megalinlox/loxApoECre and Megalinlox/lox: p<0.001). B)
Western blot of leptin levels in the urine of megalinlox/lox ApoEcre and megalinlox/lox
controls.
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We confirmed this hypothesis using PET imaging in the same mouse model.
Megalinlox/lox, ApoEcre mice were imaged using
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Ga-DOTA-leptin together with their

littermate megalinlox/loxcontrols. Our results show that in the basal condition, megalinlox/lox,
ApoEcre mice have a pattern of distribution of 68Ga-DOTA-leptin in the urinary tract that
is similar to one observed when wild type mice are co-injected with cold leptin (Figure
26a,b, compare to 21a, c). Accumulation of 68Ga-DOTA-leptin in the bladder is greatly
increased (18.7 vs. 3.5% p< 0.01) and in the kidney significantly reduced (54.5 vs.
63.7%, p<0.05) when compared to controls (Figure 26d, e). Radiochemical HPLC
analysis of the urine from a megalinlox/lox, ApoEcre mouse revealed the characteristic 21.6
min peak corresponding to intact leptin (Figure 26c). An 18F-FBA-leptin scan of the same
mouse model revealed that the residual uptake in the kidney is still concentrated in the
cortex (Figure 27a), suggesting that the remaining uptake in the kidney is either due to
the residual megalin expression, or to binding to a second receptor in the cortex of the
kidney, rather than binding to other locations in the kidney.
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Figure 26. Megalin is required for the uptake of leptin in the kidney in vivo. Coronal MIP
of a megalinlox/lox control mouse (a) injected with 68Ga-DOTA-leptin and of a megalinlox/lox
ApoEcre mouse (b) injected with 68Ga-DOTA-leptin. c) Radiochemical HPLC analysis of
urine recovered from a megalinlox/lox ApoEcre mouse, which was injected with 68GaDOTA-leptin. d, e) Time activity curves of the uptake in the kidney (d) and bladder (e) of
68
Ga-DOTA-leptin in megalinlox/lox ApoEcre (red triangles) and megalinlox/lox (blue squares)
mice. Kidney or urinary uptake on the Y-axis is defined as the total radioactivity
quantified in the kidney or bladder plus spilt urine, divided by total body radioactivity,
with both quantified by region of interest (ROI) analysis. All data are reported as mean ±
s.e.m. (n=3). Statistical significance of megalin kidney KO versus lox controls: * p <
0.05, ** p < 0.01.
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The addition of a 30-fold excess of competing leptin during micro-PET imaging
led to a further displacement of leptin from the kidney to the urine (Figure 27b, c). A
comparison of Megalinlox/lox, ApoEcre mice vs. littermate lox controls, imaged using 68GaDOTA-leptin, with co-injection of a 30 fold excess of cold leptin, reveals that the pattern
of uptake in the kidney and bladder are similar over the first 10 minutes of the scan
(Figure 27b). However, in the last 20 minutes of the scan, the lox control animals began
to again to take up leptin in the cortex of the kidney, while Megalinlox/lox, ApoEcre mice do
not. These results show that the reuptake process in the cortex of the kidney in
Megalinlox/lox, ApoEcre is exhausted following challenge with competing leptin and unable
to recover over the course of the scan. These results are consistent with the dramatically
reduced expression of megalin in the kidneys of Megalinlox/lox, ApoEcre mice. Collectively,
these data support a model of leptin renal metabolism in which leptin is freely filtered by
the glomerulus in the kidney and subsequently reabsorbed in the proximal convoluted
tubule by megalin.
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Figure 27. A) 18F-FBA-leptin scan of megalinlox/lox, ApoEcre mice reveals that leptin
uptake remains restricted to the cortex of the kidneys. B, C) Time activity curves of the
uptake in the kidney (B) and urine (C) of 68Ga-DOTA-leptin in megalinlox/lox ApoEcre (red
triangles) and megalinlox/lox (blue squares) mice, when the tracer is injected with a 30 fold
excess of competing leptin. Kidney or urinary uptake on the Y-axis is defined as the total
radioactivity quantified in the kidney or bladder plus spilt urine, divided by total body
radioactivity, with both quantified by region of interest (ROI) analysis. All data are
reported as mean ± s.e.m. (n=3).
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Section 3.6. Megalin mediates the uptake and clearance of leptin in the proximal
tubules of kidney
We have described the application of two complementary tracers, 18F-FBA-leptin
and 68Ga-DOTA-leptin to micro-PET imaging in mice. Imaging in wild type mice and
rats revealed rapid uptake in the cortex of the kidney. Additionally, lower levels of uptake
were observed in the visceral organs, head, and bone marrow. Unfortunately, probably
due to the relatively large molar quantity of tracer that had to be injected in mice,
peripheral ObR receptors were saturated under the conditions of the experiment (see
section 5.2 for discussion). Fortunately, this limitation did not apply to PET imaging in
rhesus macaques (chapter 4). Thus, in order to study quantitative ObR binding in mice,
we relied on biodistribution analysis (Figure 23, 23b, section 4.3). The unique properties
of each tracer was required for a full elucidation of the uptake of the hormone in the
kidney: while 18F-FBA-leptin revealed uptake of the hormone in the cortex of the kidney
(Figure 20, 19b), 68Ga-DOTA-leptin allowed for quantitative analysis of uptake since it is
a residualizing tracer. Furthermore, the fact that the biodistribution patterns of both
tracers are similar gives confidence in the imaging results.
Using PET imaging in mice we were able to elucidate the role of the multiligand
receptor megalin in the clearance of leptin by the kidney. Previous studies had revealed
that leptin is cleared by the kidney in mice, nonhuman primates, and humans84,85,8791,96,158,163

. We also found high levels of uptake of leptin in the kidneys in mice, rats, and

rhesus macaques (Figure 20). Quantification of uptake in the cortex of the kidney by PET
revealed that 68.2 ± 1.5% of the tracer was cleared by the kidney over 30 minutes.
Furthermore, by coinjection of a 30 fold excess of leptin, a substantial portion of the
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hormone could be displaced from the kidney, as only 47.3 ± 2.0% was then taken up.
Thus, there is a saturable reuptake system for leptin reuptake in the kidney. Recently,
Hama et al. found that leptin binds to megalin, a protein abundantly expressed on the
proximal tubules in the kidney50. Additionally, leptin had been previously shown to bind
to the renal medulla in tissue sections, where ObR is known to be expressed81,83. In order
to define which receptor was responsible for the clearance of the hormone in vivo, we
obtained mice with a kidney-specific deficit of the multiligand clearance receptor
megalin (Megalinlox/lox, ApoEcre), and mice deficient in ObR (ObRd/ob/ob). The finding
that the megalin deficient mice lost leptin in the urine suggested that this receptor was
required for the clearance of leptin. This finding was confirmed by PET imaging, where a
significant reduction of leptin uptake in the kidney was observed in mice with a kidney
specific deficit of megalin. By contrast, mice lacking ObR had no apparent change in
kidney uptake of the hormone, as detected by PET imaging. At present, we cannot
exclude the presence of a low level of ObR dependant uptake in the kidney, as
biodistribution analysis revealed a small, non-statistically significant difference in the
uptake of leptin in the kidney when comparing Ob/ob and ObRd/ob/ob mice (Figure 24c).
Thus, taken together with the previous data regarding clearance of the hormone, our PET
study reveals that leptin is freely filtered in the glomerulus of the kidney, where it is
taken up in the cortex, in a manner that requires the transporter megalin. The implications
of this finding are further discussed in section 5.3.
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Chapter 4. Ex vivo biodistribution in mice and PET imaging in rhesus macaques
reveals ObR dependant uptake of leptin in the brain and a role for leptin in
hematopoiesis

Experiments performed in this chapter were the product of a close collaboration
with G. Ceccarini (Friedman lab) and E. Butelman (Kreek lab)

Section 4.1. Why study ObR biodistribution and receptor occupancy?
The leptin receptor ObR is widely expressed in peripheral tissues and in the CNS,
and its function in the hypothalamus is essential for normal body weight and energy
homeostasis (see section 1.3)19,24. In addition, leptin modulates the function of several
peripheral tissues, in part by direct action of ObR in those organs. To date, despite
extensive study of ObR mRNA expression15,37,176, and leptin binding in tissue sections83,
there is no comprehensive description of leptin biodistribution in vivo. The advantage of
biodistribution analysis is that it takes into account the physiological (or pathological)
pattern of functional cell surface receptor expression. Furthermore, by studying the
appropriately genetically modified animals, uptake in organs and tissues can be ascribed
to specific receptors. Additionally, current models of leptin resistance, which is present in
most obese humans, predict altered biodistribution of the hormone27,177,178. Finally,
biodistribution analysis could be used to discover novel roles of leptin in an unbiased
approach.
Micro-PET imaging in mice using

68

Ga-DOTA-leptin and

18

F-FBA-leptin was

used to elucidate the mechanism of leptin clearance by the multiligand receptor megalin
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(see chapter 3). However, we were unable to study ObR mediated uptake using microPET in mice, owing to the fact that the specific activity of our tracers is moderate, and a
relatively large dose of the hormone (15-30 µg) must be injected to enable visualization
of the hormone. Unfortunately, this is a common problem in micro-PET imaging, and is
particularly prevalent in mice, which are the most convenient animals for genetic
modification179,180. One way to overcome this to this would be to improve the specific
activity of our tracers,

18

F-FBA-leptin, and

68

Ga-DOTA-leptin. Potential methods to

accomplish this are discussed in section 5.1. Another method would be to forgo PET
imaging altogether, and rely on ex-vivo biodistribution analysis, in which a smaller
quantity of a radiotracer is injected, the animal sacrificed, and the radioactivity in tissues
counted. This technique suffers from the limitations that kinetic data is more difficult to
obtain, and that the animal is destroyed in the experiment - this is particularly
troublesome for animal models that are difficult or slow to breed (for example
ObRΔ/ob/ob mice and Megalinlox/lox, ApoEcre). The final way to overcome issues of
receptor saturation is to use larger animal models such as primates. This is because a
much smaller dose relative to the mass of the animal need be injected (approximately 100
fold less in mg/kg). In this section, we describe the application of ex-vivo leptin
biodistribution analysis to mice, and of PET-CT imaging of leptin biodistribution in
rhesus macaques. Using these techniques, we found that a subset of tissues were able to
take up leptin in an ObR-dependant manner. Most prominently, hematopoietic tissues
have a very high level of uptake of the hormone, suggesting that leptin may play an
important role in modulating the function of hematopoietic and immune systems by direct
action of ObR on these cells.
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4.2 Biodistribution analysis of leptin reveals sites of leptin receptor dependant
uptake in mice
Biodistribution analysis has been previously applied to leptin (see section 1.6),
principally for the purpose of studying the transport of leptin into the brain17,39,92,181,182. We
chose to use 125I-leptin for biodistribution analysis for several reasons. Firstly, the labeled
hormone is commercially available at high specific activity (81 GBq/µmol). Secondly,
the long half-life of the isotope (60 days) means that one batch can be used for a series of
experiments. Finally, we chose to use 125I in order to avoid the regulatory problems
associated in moving animals or radioisotopes in between Rockefeller University (where
the animals were housed) to Weill-Cornell Medical College (where 18F and 68Ga is
generated).
Our goal was to define which tissues have ObR dependant uptake in mice. In
order to assess this, we investigated four groups of mice on the C57Bl6 background wild type, ob/ob (lacking intact leptin), ObRΔ (lacking all isoforms of the leptin
receptor), and ObRΔ/ob/ob (mice lacking both leptin and leptin receptor). The generation
and use of ObRΔ/ob/ob mice is necessitated because ObRΔ mice have very high
circulating levels of leptin, which would saturate any high affinity binding. By comparing
the biodistribution of leptin in an animal strain with or without competing leptin,
saturable binding sites can be identified. Secondly, by comparing the biodistribution of
leptin Ob/ob vs ObRΔ/ob/ob mice, ObR dependant binding sites can be identified. In a
typical biodistribution experiment, approximately 10-15 KBq of 125I leptin (specific
activity 81.4 GBq/µmol), corresponding to approximately 150 fmol or 2.4 ng of leptin is
injected, in the presence or absence of 650 µg competing leptin. It is important to note
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that this injected dose is approximately a 10000 fold reduction in the amount of leptin
injected in a typical micro-PET imaging experiment (20-30 µg), which could not saturate
binding sites. After 15 minutes, the animals are sacrificed by decapitation, the organs
harvested, weighed, and the radioactivity contained therein counted in a gamma counter.
Table 3A reveals the results of the biodistribution analysis of 125I-leptin in various
mouse strains. A comparison of wild type or Ob mice in the absence or presence of cold
leptin reveals the presence of saturable uptake in the spleen, lung, liver, brain and bone in
these animals (Figure 28a, c). In ObRΔ mice, no saturable uptake was seen in any organ.
An increase was seen in the uptake of the hormone in the kidney in Ob and wild type
mice when co-treated with cold leptin. As discussed in section 3.3, this is probably due to
the increased delivery of leptin to the kidney, following saturation of peripheral ObR. No
saturable uptake was seen in the heart in Ob/ob or wild type mice. Broadly speaking, our
biodistribution results are consistent with prior reports, which found uptake of 125I-leptin
in the liver, kidney, brain, and bone marrow in mice92, and in the kidney, lungs, spleen,
and liver in chickens183.
Next, we tested if ObR was required for the uptake of leptin in these tissues, by
comparing the uptake in Ob/ob vs. ObRΔ/ob/ob mice. A comparison of Ob/ob vs.
ObRΔ/ob/ob mice reveals that Ob/ob mice take up a greater amount of 125I-leptin in the
spleen, lung, liver, brain, bone and fat than their ObRΔ/ob/ob counterparts (Figure 28b,
c). Thus, there is ObR dependant uptake in these tissues. The fact that there was a
difference between Ob/ob vs. ObRΔ/ob/ob mice in the uptake of 125I-leptin in the fat, and
saturable uptake of leptin in the fat of Ob/ob but not wild type mice, suggests that there is
functional leptin receptor in fat tissue, but that it is saturated under the conditions of the
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experiment in wild type mice. Alternatively, Ob mice may upregulate ObR in fat tissue to
compensate for their leptin starved state.
One major caveat in interpreting the data in this manner is that there is a
significant variation in blood levels of leptin between the different strains of mice (Table
3a). The cause of this phenomenon is obscure, but may be due to saturation of circulating
receptors (ObRe), or other intravascular binding sites. In order to correct for this
phenomenon, we present the same data again on Table 3b, where the uptake in tissues is
divided by the uptake in the blood, and then multiplied by 1000 by convention to enable
comparison with published results17,39. This correction allows for a direct comparison of
the binding potential for leptin in an organ of an animal to that of other organs within the
same animal or others. A more rigorous method would be to serially take blood samples
to define an “exposure time” parameter17,184,185. However, given the difficulty in
generating the correct mouse strains in significant numbers (particularly ObRΔ/ob/ob
mice, which must be generated from a cross of double ObRΔ/ob heterozygotes) this is an
intractable problem from a technical standpoint. Nevertheless, given that we are simply
seeking to define regions of saturable uptake, and to explain which receptor is
responsible, this analysis is sufficient.
Broadly speaking, the results from the corrected biodistribution mimic those of
the unmodified numbers, revealing saturable, leptin receptor dependant uptake in the
spleen, lung, liver, brain, bone, and fat. An additional interesting observation is that there
is higher binding in all tissues in Ob mice vs. wild type mice, suggesting either that Ob
mice upregulate ObR to compensate for their leptin starved condition, or that wild type
mice have their binding sites partially saturated under physiological conditions. Our data
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reveal slightly higher uptake of 125I-leptin in the brain than previous reports, possibly
owing to either different specific activity of our 125I-leptin preparation, different mouse
strains (CD-1 vs. C57Bl6 in our study) or different dissection technique (Figure 29, value
of 55 in wild type mice, compare to approximately 25 in intact animals17, but ranging
from 10-125 using perfusion techniques 39,182). A comparison of the brain uptake of leptin
in Ob/ob and ObRΔ/ob/ob mice reveals a significantly different level of uptake in the
brain, implying that ObR is required for uptake of leptin in the brain. These data
represent the first unambiguous demonstration that leptin receptor is required for full
transport and binding of leptin to the brain under intact physiological conditions. Using a
capillary perfusion technique, in which mouse brains were perfused with 125I-leptin,
Hileman et al. found a significant difference between the uptake of 125I-leptin when
comparing wild type and ObRΔ mice39. Our data confirm this finding, and extend it to
find that the reduced uptake also occurs in mice under physiological, non-brain perfused
conditions. Furthermore, this finding controls for the multiple endocrine and immune
abnormalities found in Ob and ObRΔ mice.
Our data reveal that the highest level of uptake of leptin in the brain is in Ob
mice. Wild type mice have lower uptake, suggesting that their uptake system into the
brain is either lower capacity or partially saturated, consistent with previous
observations182. All animals with competing cold leptin, or lacking leptin receptor
altogether, have lower levels of leptin uptake in the brain. Taken together, our data reveal
that in mice, that there is saturable, ObR dependant uptake of leptin in the spleen, lung,
liver, brain, bone, fat, and possibly in the kidney.
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A)

Blood

7.24 ± 0.13

WT + cold
leptin
4.33 ± 0.09

3.90 ± 0.16

Ob/ob +
cold leptin
3.16 ± 0.21

4.33 ± 0.16

ObRΔ +
cold leptin
2.56 ± 0.38

Spleen

20.40 ± 4.02

2.42 ± 0.31

15.70 ± 1.80

2.96 ± 0.73

1.50 ± 0.42

1.33 ± 0.39

5.84 ± 0.39

Lung

11.47 ± 2.93

3.23 ± 1.45

11.05 ± 0.56

3.37 ± 0.32

2.90 ± 0.84

1.86 ± 0.43

3.89 ± 0.43

Liver

4.28 ± 0.14

1.44 ± 0.13

4.08 ± 0.53

1.36 ± 0.22

1.09 ± 0.01

0.84 ± 0.22

1.80 ± 0.22

Heart

3.70 ± 0.36

2.66 ± 0.10

1.85 ± 0.15

2.03 ± 0.04

2.15 ± 0.16

1.98 ± 0.33

1.98 ± 0.33

Brain

0.40 ± 0.01

0.19 ± 0.02

0.26 ± 0.02

0.14 ± 0.01

0.15 ± 0.03

0.09 ± 0.02

0.18 ± 0.02

Bone

3.52 ± 0.055

1.23 ± 0.44

1.55 ± 0.06

0.71 ± 0.05

0.90 ± 0.06

0.65 ± 0.07

0.88 ± 0.07

Fat

1.04 ± 0.18

1.14 ± 0.07

0.50 ± 0.06

0.30 ± 0.05

0.37 ± 0.03

0.23 ± 0.03

0.35 ± 0.04

Kidney

49.1 ± 12.1

125 ± 13

27.6 ± 2.4

96.5 ± 13.9

60.7 ± 5.5

85.6 ± 3.1

29.9 ± 3.9

Organ

WT

Ob/ob

ObRΔ

ObRΔ/ob/ob
6.05 ± 0.45

B)

2817 ± 557

WT + cold
leptin
558 ± 73

1584 ± 405

745 ± 335

Organ

WT

Spleen
Lung

4028 ± 493

Ob/ob +
cold leptin
936 ± 240

348 ± 53

ObRΔ +
cold leptin
519 ± 171

2835 ± 187

1065 ± 123

672 ± 196

727 ± 200

644 ± 57

Ob/ob

ObRΔ

ObRΔ/ob/ob
966 ± 130

Liver

590 ± 22

333 ± 30

1047 ± 142

428 ± 76

253 ± 10

332 ± 100

298 ± 49

Heart

510 ± 51

615 ± 26

475 ± 44

644 ± 43

498 ± 42

773 ± 174

445 ± 31

Brain

55 ± 2

44 ± 6

66 ± 5

43 ± 5

36 ± 7

34 ± 9

30 ± 4

Bone

486 ± 12

295 ± 12

398 ± 22

225 ± 21

209 ± 17

254 ± 48

146 ± 14

Fat

145 ± 25

263 ± 18

127 ± 17

95 ± 16

86 ± 7

90 ± 18

58 ± 7

Kidney

6783 ± 414

28887 ± 336

7083 ± 66

30533 ±
2620

14017 ±
641

33497 ±
5041

4945 ± 450

Table 3. Summary of biodistribution analysis of 125I-leptin in various mouse models. A)
Uptake in % injected dose/g tissue (i.e., the percent of the total injected dose in a tissue,
divided by the weight of that tissue). Results are an average of 3-4 experiments ± s.e.m.
B) Uptake in the indicated tissues when corrected for blood values. Uptake values from A
were divided by the blood uptake value, and multiplied by 1000 to obtain a normalized
standard uptake value. Results are an average of 3-4 experiments ± s.e.m.
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Figure 28. Biodistribution results using 125I reveal saturable and leptin receptor
dependant uptake in tissues. Animals were sacrificed 15 minutes after injection with 15
KBq 125I-leptin, and the indicated tissues weighed and counted in a gamma counter. The
% of the total injected dose in the indicated tissue, divided by the weight of the tissue is
plotted on the Y-axis. A) A comparison of wild type and Ob/ob mice with and without
coinjection with 650 µg leptin. B) A comparison of Ob/ob vs ObRΔ/ob/ob. C) A
comparison of the uptake of leptin in the brain in various animal models.
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Figure 29. Uptake of 125I-leptin in the brain is mediated in part by ObR. Animals were
sacrificed 15 minutes after injection with 15 KBq 125I-leptin, and the brain and blood
were collected, weighed, and counted in a gamma counter. On the Y axis the uptake is
represented as 1000 times (% Injected dose / mass of brain in mg) / (% injected dose in
blood / mass of blood in mg), i.e. the standard uptake value of leptin in the brain when
using the blood as a reference tissue (n = 3-4 ± s.e.m). Statistical significance was
assessed between the Ob/ob group and the other groups connected by lines by Student’s
one-tailed t-test, 0.05 < p.
Section 4.3. A rationale for imaging of leptin biodistribution in non-human primates
The encouraging results generated from micro-PET imaging and biodistribution
studies in rodents led us to consider other animal model systems with greater relevance to
leptin biology in man. Rhesus macaques are a commonly used species of laboratory
monkey in which the basic physiology of leptin has been characterized, using essentially
the same approaches followed in mice. The cloning of rhesus macaque leptin followed
shortly after the cloning of mouse and human leptin186. The sequence homology of rhesus
to mouse and human leptin is 84% and 91%, respectively (Figure 30). Rhesus ObR is
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found in adipose tissue, liver, choroid plexus, and hypothalamus, where it is expressed
principally in the arcuate and ventromedial hypothalamic nuclei in POMC and AgRP
neurons172,187. Leptin levels in macaques are correlated with the total weight of the animal,
and centrally administered human leptin is able to induce weight loss while peripherally
administered leptin is not188,189. Leptin has a biphasic half-life in macaques with a secondphase half life of 96 minutes86. Leptin also appears to play a role in the immune system in
macaques, as they produce leptin in response to endotoxin injection190. Furthermore,
leptin treatment reduces the production of other inflammatory factors such as IL-6, TNFα, and cortisol in endotoxin injected monkeys191. Thus, the role of leptin in energy
homeostasis and regulation of immunity superficially resembles the homologous system
in mice. It is likely that further study of leptin physiology in macaques will yield useful
information of relevance to humans.
PET imaging of leptin biodistribution in rhesus macaques provides additional
information which could not be obtained in mice. Firstly, leptin function and physiology
is more likely to mimic that in humans due to the closer evolutionary relationship
between the species. Secondly, due to their larger size, Macaques can be imaged in a
clinical PET-CT scanner. Thus, the functional metabolic information provided by the
PET scan can be fused to the anatomical information provided by the CT scan.
Additionally, a lower dose of isotope relative to the size of the animal can be injected,
which reduces saturation of receptor binding sites. Therefore, we decided to undertake a
PET study of leptin biodistribution in rhesus macaques.
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Figure 30. Sequence alignment of leptin in mammalian species referred to in this section.
Sites of divergence are highlighted in red. Residues which are believed to be essential for
ObR binding or activation133,134 are highlighted in blue.
4.4. PET imaging of leptin biodistribution in rhesus macaques.
In a typical PET-CT imaging experiment, 68Ga-DOTA-leptin is introduced via a
venous catheter, with or without 1 mg of competing cold leptin administration prior to
tracer administration. PET imaging of rhesus macaques injected with 68Ga-DOTA-leptin
revealed a high level of uptake in the sphenoid bone, mandibles, head of the humeri,
vertebral bodies, pelvic bones, sternum, and kidney (Figure 31a-d). PET-CT fusion
images reveal that the tracer is confined to the inner portion of these bones (Figure 32).
One possibility is that this binding represents an artifact of imaging the biodistribution of
murine leptin in a rhesus monkey. In order to exclude this possibility, we performed a
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competition experiment in which rhesus leptin was used to displace 68Ga-DOTA(murine)-leptin in a PET imaging experiment. Thus, we expressed rhesus leptin in E. coli
and purified and refolded it as described in the methods (Figure 33A, B). In the
aforementioned (murine) ObRb-STAT3-luciferase activation assay (Figure 6), rhesus
leptin had identical activity to human leptin (Figure 33C, EC50 of 0.44 nM). In a 68GaDOTA-leptin scan with the coinjection of a 20-fold excess of rhesus leptin, a striking
difference was observed, and the tracer localized almost exclusively to the kidney (Figure
31e, f). Nearly identical results were obtained with a similar competition scan with
murine leptin (data not shown). Thus, the binding of 68Ga-DOTA-leptin to these tissues
almost certainly mimics the binding activity of rhesus leptin.
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Figure 31. Maximum intensity projections (MIPs) of PET scans using 9 – 25 MBq of
68
Ga-DOTA-leptin (corresponding to approximately 50 µg) as a tracer in rhesus
macaques. A,B) Subject #1, in coronal and sagittal planes. C,D) Subject #2 in coronal
and sagittal planes. E,F) Subject #1, with 1 mg of competing cold rhesus leptin coinjection, in coronal and sagittal planes.

90

Figure 32. PET-CT fusions of two rhesus macaques injected with 68Ga-DOTA-leptin
(10-30 MBq per experiment). A) Subject #1, sagittal view at midline. B) Subject #1, axial
view at the base of the skull. C) Subject #2, sagittal view at midline. D) Subject #2, axial
view at the base of the skull. E) Subject #2, axial view through the L4 vertebral body. F)
Subject #2, axial view through the sacrum.
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Figure 33. Expression and purification of rhesus leptin. a) SDS-PAGE on a 4-20%
gradient gel of purified rhesus leptin, stained with Coomassie blue. b) ESI-MS
reconstruct of purified rhesus leptin (Calculated mass 16529.1, obtained 16529.7 ± 4.1).
c) Leptin receptor-STAT3 dependant luciferase assay comparing the activity of rhesus
leptin and human leptin obtained from a commercial source. EC50 for rhesus leptin = 0.44
nM (95% confidence intervals 0.37 – 0.53 nM). EC50 for human leptin = 0.42 nM (95%
confidence intervals 0.32 to 0.54 nM, n = 2 per group ± s.d).
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The high level of uptake of the tracer in the kidney likely represents uptake in the
proximal convoluted tubule by the endocytic receptor megalin (see chapter 3). The
pattern of uptake in the sphenoid bone, sternum, head of the humerus, and vertebral
bodies mimics that obtained with the bone marrow targeting tracer 18F-fluorothymidine
(FLT)192. Based on the similarity between the images generated with these two tracers,
we propose that the high levels of uptake in the axial skeleton represent binding to red
bone marrow. Red bone marrow is the site of hematopoiesis in adult rhesus macaques,
and is composed of hematopoietic precursors, blood vessels, and stromal cells such as
adipocytes and reticular cells.
Time activity curves of uptake of 68Ga-DOTA-leptin are presented on Figure 34.
Four distinct patterns of uptake were observed. Firstly, radioactivity in the bone marrow
stays constant over time course of the scan, at a high level. This pattern suggests the
presence of a very high level of saturable receptors. The tracer accumulates continually in
the kidney over the course of the scan, mimicking the effect observed in mice (see Figure
22e). This pattern is consistent with the clearance of the hormone by the receptor megalin
in the kidney (see chapter 3). Interestingly, displacement increased the activity observed
in the kidneys. These results are consistent with a high affinity-binding site in the bone
marrow (presumably leptin receptor), and a lower affinity site in the kidneys (presumably
megalin). Thus, in the absence of competing leptin, the tracer is free to bind to peripheral
leptin receptors. However, in the presence of saturating leptin, binding to the high affinity
sites is blocked, and leptin is instead filtered by the kidney, where it binds to megalin, in
a lower affinity interaction. In comparison with mice, the rate of clearance of 68GaDOTA-leptin in rhesus macaques is slower, as judged by the uptake of the hormone in
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the kidney (compare Figure 22e and 35); this is consistent with a previous comparison of
leptin pharmacokinetics in mice and monkeys86. In the heart, an identical pattern of
disappearance of the tracer is observed in the displacement and tracer-only scans. This
pattern suggests that there is no saturable uptake in the organ, and that the observed
radioactivity simply represents intravascular leptin. Finally, the liver initially has the
same level of the tracer, but as the scan progresses, the tracer clears more rapidly from
organs in the competing scan than in the tracer-only scan. This pattern suggests the
presence of a low level of saturable receptors in the organ, which is initially
overshadowed by the blood pool leptin. As the leptin in the blood clears to the kidney, the
saturable uptake becomes detectable. Thus, collectively these data indicate that there is
the presence of a very high level of saturable uptake leptin in the bone marrow, and lower
levels of uptake in the liver.

94

Figure 34. Time activity curves of uptake of 68Ga-DOTA-leptin in rhesus macaques in
selected organs. Uptake on the Y axis is the fraction of the injected dose in the
corresponding tissue, i.e. the total radioactivity in the indicated tissue, divided by the total
body radioactivity, as determined from ROI analysis of the PET-CT fusion scan (average
of two animals per group +/- s.e.m.)
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4.5. A comparison of mouse biodistribution and rhesus monkey PET results suggests
a role for leptin in hematopoiesis
In order to define the molecular mechanism of leptin uptake in various
tissues, we performed biodistribution analysis using 125I leptin in mouse models. Using
this method, saturable, ObR dependant uptake of the hormone was found in the brain, fat,
spleen, lung, liver, and bone (Figure 28a). Of these tissues, the spleen and bone are sites
of hematopoiesis in adult mice193. Additionally, biodistribution analysis in mice lacking
leptin receptor reveals that the uptake in these sites is dependant on ObR (Figure 29).
Uptake in the fat was relatively low, and saturated in wild type mice, suggesting that
these receptors are generally saturated under normal physiological conditions. The low
level of saturable uptake in the brain is consistent with previously published results17,39.
Importantly, our results provide direct proof that leptin receptor mediates binding in the
mouse brain, and that this system is not fully saturated under normal physiological
conditions (Figure 29). At present, our results also suggest a low level of ObR mediated
leptin uptake in the kidney, in addition to the much higher level of megalin mediated
uptake, although a larger data set is needed to conclusively prove this hypothesis. Much
higher levels of ObR dependant leptin uptake were also seen in the lungs, liver, bone, and
especially in the spleen.
In rhesus macaques, saturable uptake of the hormone was found in the bone
marrow and liver (Figure 34). Uptake in the bone marrow was particularly prominent
(Figure 31, 32). In adult primates, the bone marrow is the site of hematopoiesis193.
Unfortunately, the same quantitative technique could not be applied to understanding the
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biodistribution of leptin using PET imaging in mice. This is because a relatively large
amount of tracer must be injected in mice (15-30 μg per scan), potentially saturating
peripheral binding sites. Nevertheless, we were able to see a low level of tracer uptake in
the bone marrow in rats injected with 68Ga-DOTA-leptin (see Figure 20c). Another
important result is that the highest level of uptake was observed in the hematopoietic
system in mice (in the spleen and bone marrow), and in rhesus macaques (the bone
marrow). Taken together, these results strongly suggest that leptin plays a role in
modulating the immune and hematopoietic systems by direct action on hematopoietic
precursors.
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Chapter 5. Discussion
5.1. A comparison of the properties of 18F-FBA-leptin and 68Ga-DOTA-leptin, and
potential improvements to the tracers
The properties of the three radiolabeled tracers referred to in this thesis are
presented on Table 4.

68

Ga-DOTA-leptin and 18F-FBA-leptin emit positrons, allowing for

PET imaging, while 125I decays by electron capture to produce β- particles which cannot
be used for PET imaging. The specific activity of the PET-imaging tracers is
comparable, with that of 18F-FBA-leptin being slightly higher than 68Ga-DOTA-leptin.
The major advantage of the 18F-FBA-leptin tracer is the resolution of the images
generated. Thus, while imaging of 68Ga-DOTA-leptin reveals uptake of the tracer in the
kidney, the higher resolution of 18F-FBA-leptin shows that the protein is absorbed
principally in the renal cortex (Figure 20, 19). The labeling chemistry and protein
labeling sites are different, but both PET tracers retain native-like bioactivity (Figures 7,
14). Finally, the fate of the labeled tracers following receptor binding and endocytosis are
different: 68Ga-DOTA-lysine a residualizing tracer, while the unidentified metabolite of
18

F-FBA-leptin diffuses freely from cells, as does 125I-iodotyrosine from 125I-leptin treated

cells (Figure 21). It is important to note that there were no detectable physiological
effects of any labeled tracers in any PET imaging experiments we performed,
demonstrating that we were performing our imaging experiments at tracer levels.
Furthermore, the similar biodistribution pattern generated by all tracers used provides
confidence that the modified proteins mimic the behavior of intact leptin.
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68

Tracer

Ga-DOTAleptin

Specific
activity

5.5 - 11 GBq /
µmol

9 - 17 GBq / µmol

81 GBq / µmol

Half-life

68 minutes

110 minutes

60 days

Imaging
resolution

2.3 - 11.5 mm

0.65 - 2.7 mm

No imaging

Labeling
sites

Amines (lysine
and Nterminus)

C-terminus

Tyrosines

Labeling
method

Metal
chelation

Oximation

Peroxidase mediated
iodination

Intracellular
metabolism

Residualizing

Diffusible

Diffusible

18

F-FBA-leptin

125

I-leptin

Table 4. A comparison of the properties of the three radioactive tracers used in this
thesis. Resolution information is taken from the model study of Sanchez-Crespo et al101.
A comparison of 68Ga-DOTA-leptin to the other 68Ga-chelate labeled proteins
from the literature is presented on Table 5. The radiochemical properties of our tracer
compares favorably with the previously reported 68Ga labeled leptin derivative. The
improved yield of the radiochemical synthesis for 68Ga-DOTA-leptin is likely due to the
high stoichiometry of chelator to protein (4:1), when compared to the prior report (1:1)97.
The synthesis of 68Ga-DOTA-leptin is highly optimized with respect to temperature,
concentration of the protein, and time of reaction, and is not likely to improve. Thus, the
only way to improve this tracer would be to start with more 68Ga. During the course of
our experiments the 68Ge/68Ga generator produced 0.15-0.3 GBq of 68Ga, while generators
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producing up to 3.7 GBq are commercially available. A 10-20 fold improvement in
specific activity could easily be obtained by using such a generator. An alternate method
would be to use 64Cu to label DOTA-leptin. This isotope has recently become popular
owing to the high resolution of the images it generates (Bmax of 0.65 MeV, comparable
to 0.63 MeV for 18F, see table 2)105. For example, a 64Cu labeled vascular endothelial
growth factor (VEGF) derivative has recently been applied to PET imaging in various
animal models194-197. The major drawback in the use of this isotope is the half-life of 12.8
hours and the low percentage of positrons it emits (18%), which results in a high
radiation burden to any animal in which it is injected.
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Ref

Protein

Chelator

Yield
(%)

Specific
activity

198

Antibody

DTPA

N.R.

N.R.

97

Leptin

DTPA

N.R.

1.7 - 6
GBq/μmol

137

LDL

DTPA

N.R.

0.1850.370
GBq/mg

199

Albumin

DOTA

45

11
GBq/μmol

138

EGF

DOTA

N.R.

12-20
GBq-μmol

90 degree microwave
labeling

Leptin

DOTA

25.7
± 4.7

5.5 - 11
GBq/μmol

0.15 - 0.37 Gbq generator

Chapter
2

Note

3.7 GBq generator

Table 5. A comparison of 68Ga-DOTA-leptin to previously reported 68Ga protein tracers.
N.R. = not reported.
18

F-FBA-leptin is compared to other 18F labeled proteins reported in the literature

on Table 6, and Figure 35. Our labeling method, based on expressed protein
ligation144,200, is unique among the 18F labeling techniques in that it is intrinsically sitespecific and directed to the C-terminus163. Furthermore, the yields of the two reactions in
our synthesis, the preparation of 18F-FBA and the aniline-accelerated oximation, are
comparable to the best methods published. However, the specific activity of 18F-FBAleptin order of magnitude lower than the best prior reports of 18F-labeled proteins159,201,202.
This is for three reasons: firstly, the reformulation of 18F-FBA into water is time
consuming, and requires multiple handling steps. Furthermore, as our synthesis is
manual, a relatively small amount of starting radioactivity can be used due to safety
concerns. Finally, the recovered yield of our labeling reaction is relatively low owing to a
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tendency of our labeled protein to precipitate. Finally, due to the tendency of leptin to
precipitate, we must perform our labeling reaction on ice. Most prior 18F labeling
reactions have been conducted at elevated temperatures, which accelerates the
conjugation. Optimization of the synthesis along the lines of several previous reports
could considerably improve the specific activity of our protein, allowing for a superior
imaging probe.
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Ref

Protein

Target

Labeling
reagent
yield (%)

Protein
labeling
yield (%)

Overall yield
(%)

Specific
activity
(GBq/μmol)

Reagent

Method

125

Albumin

Amine

67 ± 15.7

25-90

N.R.

N.R.

7

Manual

203

Albumin

Amine

50 - 60

90

N.R.

N.R.

8

Manual

124

Albumin

Amine

50

N.R.

15

N.R.

9

Manual

204

Annexin V

Amine

N.R.

N.R.

N.R.

0.02 - 0.033

8

Manual

202

Annexin V

Amine

N.R.

N.R.

15-20

35

8

Automated

205

Annexin V

Amine

N.R.

70

17.6 ± 5.6

1.3

8

Manual

206

Antibody

Amine

N.R.

N.R.

39

11

8

Manual

207

Antibody

Amine

25

50

N.R.

N.R.

8

Manual

208

Antibody

Amine

30 - 35

15 - 20

3

3.7 - 40

8

Manual

209

Antibody

Amine

25

N.R.

0.5

12-17

8

Manual

210

Antibody

Amine

N.R.

25 - 40

N.R.

18

10

Manual

159

Epo

Amine

16.5

19.8 ± 5.2

N.R.

147

8

Manual

201

Transferrin

Amine

N.R.

N.R.

N.R.

37 - 74

8

Manual

Leptin

C-terminus

40 - 70

65

3

9.25 - 16.65

7

Manual

211

Affibody

Cys

50-70

N.R.

13 - 18

10.4 - 20.8

7

Automated

131

Annexin V

Cys

45-69

43 - 58

N.R.

2-4

11

Manual

132

Annexin V

Cys

23 ± 4

37 ± 9

N.R.

N.R.

12b

Manual

163
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Ab fragment

Cys

28-37

60-70

N.R.

N.R.

12a

Manual

128

LDL

Cys

29

17 ± 10

N.R.

50 - 300

12c

Manual

212

MS2 phage

Tyr

65 - 75

15 - 25

N.R.

N.R.

7

Manual

Table 6. A comparison of well characterized methods for labeling proteins with 18F from
the literature.
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Figure 35. Previously described 18F-based synthons for protein labeling, referred to on
table 7.
The synthesis of 18F-FBA-leptin could be improved in several ways. Firstly,
automation of the synthesis of 18F-FBA, as previously reported211, would allow for an
increase in starting radioactivity of up to five fold, since a limiting factor in the amount of
radioactivity is the dose of radiation to the hands of the operator. In the labeling of 18FFBA-leptin, a paradoxical decrease of labeling efficiency was observed when increasing
portions of the 18F-FBA product was added to aminooxy-leptin 4, suggesting that the 18FFBA prep contains impurities which interfere with or compete with the reaction.
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Consistent with this was the finding that intact aminooxy-leptin 4 was not observed in the
radiochemical product of the labeling reaction, but instead only a mixture of products
with a higher mass were found (data not shown). Therefore it is likely that the specific
activity of the 18F-FBA is moderate and may represent the limiting factor in generating
high specific activity leptin. Optimization of the purification conditions and
reformulation of 18F-FBA, along the lines of a recent report132, would improve its specific
activity. Another option would be to forgo the use of 18F-FBA altogether, and to instead
use 18F-fluorodeoxyglucose (FDG). 18F-FDG is the most commonly used PET tracer, and
a recent study revealed that it could be used to label small molecule substrates (e.g.
compound 11, Figure 35) by oximation131. It is likely that using aniline to accelerate this
reaction would render it useful for protein labeling. These improvements in the
generation of the 18F synthon for leptin labeling would likely lead to an improved
radiotracer.
Finally, it is likely that altering the structure of the aminooxy-leptin used as a
precursor would improve the stability of the labeled leptin. One simple method to
accomplish this would be to dramatically shorten the linker length between the protein
and the aminooxy group. For example, the length of the linker could be reduced from 29
atoms (Scheme 1) to 2 atoms by expressed protein ligation with the reagent in Scheme
5A. This compound could readily be synthesized from previously described N-[2-(tertbutyl-N-hydroxycarbamoyl)ethyl]amine213 in two steps (Scheme 5B). This compound
could be conjugated to leptin using expressed protein ligation, similar to the technique
shown on Scheme 2. Based on experiments in which other small moieties were installed
at the C-terminus of leptin (data not shown), the smaller linker would likely have greater
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stability and bioactivity than the previously described 18F-FBA-leptin. Alternatively, the
lysine-directed aminooxyacetic acid / 18F-FBA strategy (Section 2.5) could be further
explored and applied to imaging in vivo. It is likely that implementing these
improvements to both the protein chemistry and the radiochemistry would substantially
increase the specific activity of the final tracer. In turn, the improved specific activity of
these tracers could potentially allow for better visualization of high affinity, low capacity
interactions of leptin, such as transport into the brain, by micro-PET imaging in mice.
Furthermore, the optimization of the specific activity of the tracer is crucial for
translation of the imaging methodologies to human subjects.
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Scheme 5. A) Structure of proposed short-aminooxy Cys-linker. B) Proposed synthesis
for short aminooxy Cys-linker.

5.2. Biodistribution results and discussion
Our study of leptin biodistribution represents the most extensive report to date.
Van Heek et al. studied leptin biodistribution using 125I leptin; however doses of the
hormone were used which saturate peripheral receptors (injected dose of 0.3 mg/kg)92.
Nevertheless, they were able to observe leptin binding in the bone marrow. Karonen et al.
studied leptin biodistribution using SPECT, finding uptake in the liver, kidneys, lung, and
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brain96. One study used 125I-leptin to study leptin transport across the placenta in
pregnancy in rats214. In chickens, leptin has a very high level of uptake in the kidney, but
also in the testes, lung, and spleen183. Several studies have used 125I-leptin to study the
transport of leptin into the brain17,39,182,215,216. Collectively, these previous biodistribution
studies have suffered from a lack of displacement studies using cold ligand, and no
molecular characterization of binding sites has been performed. Thus, to date there is no
comprehensive description of leptin biodistribution.
Our results incorporate data from three different labeled molecules, 68Ga-DOTAleptin, 18F-FBA-leptin, and 125I-leptin, in model systems including mice, rats, and rhesus
macaques. A comparison of our experiments reveals largely consistent results, when the
effect of injected dose is considered (see Table 7). The different results obtained in
micro-PET and ex vivo biodistribution experiments are likely the result of receptor
saturation at both high affinity receptors (ObR) and low affinity receptors (megalin) and
can be summed up as follows. In the case where a very small amount of tracer is injected,
relative to the size of the animal, such as in ex vivo biodistribution studies using 125I-leptin
and 68Ga-DOTA-leptin, and in PET imaging in rhesus macaques using 68Ga-DOTAleptin, there is no saturation of high affinity receptors. In intermediate cases, including
micro-PET imaging in mice using 68Ga-DOTA-leptin and 18F-FBA-leptin, or PET
imaging in rhesus macaques with a small amount of competing leptin, high affinity
peripheral receptors are saturated (ObR). Thus, micro-PET imaging in mice has been
useful principally for studying the low affinity interaction of leptin with megalin. The
final case is biodistribution and PET imaging experiments in mice, where a high dose of
competing leptin is co-injected, saturating both high affinity (ObR) and low affinity
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receptors (megalin). Collectively, our biodistribution and PET results suggest that
megalin is a low affinity receptor for leptin in the kidney, and ObR is a high affinity
receptor for leptin in the bone marrow, lung, liver, fat, spleen, and brain.

Injected
dose
Weight
of
animal
Injected
dose
(mg/kg)

PET
imaging in
rhesus
macaques
with
displacement

Mouse
biodistribution

Micro
Pet in
mice

Mouse
displacement
experiments

Micro
PET
in rats

PET
imaging
in rhesus
macaques

<100 ng

20-30
μg

650 μg

60 μg

60 μg

1000 μg

30g

30g

30g

500g

10 kg

10 kg

<0.003

0.66-1

22

0.12

0.006

0.1

Table 7. Summary of effective doses delivered in different animal experiments
performed in this thesis.
The uptake of leptin in the kidney by megalin is discussed in section 5.3, the
uptake in the spleen and bone marrow by ObR is discussed in section 5.4, and in the brain
in section 5.5. Our biodistribution results in mice and PET imaging in rhesus macaques
also reveal uptake of leptin in the lung, liver, and fat. Although ObR mRNA is found in
both lung and liver, its physiologic effects in these tissues remains unclear. ObRb is
abundantly expressed in the lung37, while the short isoforms (ObRa, c, and f) are more
abundantly expressed in the liver217. The role of leptin in the physiology of the lung is
less clear than in other organs. It is possible that our data represent binding to resident
immune cells of the lung, as leptin receptor positive T-cells are present in large numbers
in this organ218. Dal farra et al also found that leptin binding sites are present in the
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pulmonary parenchyma as well as bronchiolar epithelium83. It is likely that these cells are
the ones that leptin is bound to in our study.
The relatively low uptake of leptin in the liver compared to other organs (4.1 ±
0.1% ID/g for liver vs. 24.8 ± 4.0% ID/g for spleen in mice) suggests that leptin may only
bind to a subset of cells in the liver, or that liver cells expressed relatively little ObR.
Leptin induces IRS-1 phosphorylation in cultured HEP-G2 hepatocytes, in a manner that
mimics insulin signaling219-221. However, a tissue specific knockout of leptin receptor in
hepatocytes resulted in no apparent metabolic phenotype, revealing that this effect is not
required for normal glucose homeostasis18. Leptin also has a direct effect on hepatic
stellate cells, inducing collagen production and promoting fibrosis222. One study
suggested that leptin receptor in the liver was induced by both leptin treatment and shortterm starvation. In particular, ObRe production was enhanced, suggesting that the liver
may act as a reservoir of the circulating leptin receptor223. Thus, while our results
showing leptin:ObR binding in the lung and liver are consistent with mRNA expression
data in mice, the physiological effect of leptin in these tissues remains unknown. The
identification of which cell types leptin is binding to in the lung and liver could provide a
starting point for identifying the physiological role of leptin in these tissues.
We also found saturable uptake of leptin in the fat of Ob, but not wild type mice
(Table 3b). This suggests either that these receptors are saturated under physiological
conditions, or that hypoleptinemic animals such as Ob mice upregulate ObR. The role of
ObR in the fat tissue is currently obscure. Some experiments have suggested that the
action of ObR is required for full lipolysis to take place in the tissue71,72. Our finding, that
there is no saturable uptake of leptin in fat tissue in normal wild type mice, suggests that
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the ObR receptor on fat may play a role in fasting or starving conditions. For example,
under conditions of starvation, a lack of ObR signaling on adipocytes could act to alter
the metabolism of the adipocytes. As a first step in evaluating this hypothesis, the uptake
of 125I-leptin adipose tissue in fasted wild type mice and rats could be evaluated and
compared to well fed animals.

5.3 Leptin and megalin in the kidney, and potential implications of the
megalin:leptin interaction
Our study is the first, to our knowledge, to utilize PET to systematically
investigate leptin biodistribution in the kidney. We found a similar biodistribution
pattern, in which leptin is taken up in the cortex of the kidney, in mice, rats, and rhesus
macaques (Figure 20). In both humans and rodents, leptin has a short half-life, and
kidneys are the major site of leptin metabolism from the circulation, accounting for over
80% of all clearance from plasma12,84,87,88. The half-life of leptin appears to be unaffected
in ob/ob, db/db, or mice on a high fat diet92,224. Our finding of rapid and identical kidney
uptake in ob/ob, ObRΔ/ob/ob, and wild type mice, with approximately 50% of the total
hormone appearing in the kidney 3 min post injection, is consistent with these studies
(Figure 24a). End stage renal disease (ESRD) causes increased leptin levels164 and this
increase could underlie the induction of anorexia, a symptom associated with ESRD225.
Thus, the clearance of potent low molecular weight hormones such as leptin by the
kidney is a problem of clinical significance.
Several studies have shown that leptin metabolism in the kidney is the result of an
active process165. Conflicting reports suggested that leptin uptake in the kidney is
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saturable84 or non saturable158. The evidence that both the long (ObRb) and one of the
short (ObRa) isoforms of leptin receptor are expressed mainly at the loop of Henle50 in
the kidney, and are capable of mediating internalization of leptin in vitro93, makes them
candidate leptin transporters in that organ. ObRb may also mediate a possible natriuretic
effect of leptin226. In vitro binding experiments performed with

125

I-leptin on kidney

preparations have shown binding exclusively at the level of the medulla, which could be
compatible with ObR distribution81.
However, we have presented several lines of evidence that unequivocally
demonstrate that megalin (gp330/LRP2), and not ObR, is required for leptin metabolism
in the kidney in vivo. Our results in 3 different mammalian species (mouse, rat, and
rhesus macaques) show that leptin is actively taken up in the renal cortex, which is not
compatible with the aforementioned pattern of leptin receptor expression. Furthermore,
leptin uptake in the kidney was not significantly reduced in ObRΔ animals, which lack
leptin receptor. Recently, Hama et al. found that megalin (gp330/LRP 2) binds leptin with
an apparent affinity of 300 nM in QCM analysis and can mediate leptin uptake in an L2
yolk sac tumor cell line50. Megalin is highly expressed at the proximal convoluted tubule
in the kidney cortex. It is involved in endocytosis of several ligands, including hormones
and their precursors (PTH, insulin, prolactin, EGF, thyroglobulin) vitamin binding
proteins (Vitamin-D binding protein, retinol binding protein, transcobalamin-VitB12) and
carrier proteins (Haemoglobin, myoglobin, albumin, lactoferrin, transthyretin)50,167.
Megalin knockout mice are severely compromised due to a deficit in the development of
the forebrain (holoprosencephaly) and die perinatally227. Megalin kidney specific
knockout mice (megalinlox/lox, ApoEcre) show a normal phenotype but reduced kidney
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uptake of several megalin ligands175,228,229. We have demonstrated that megalinlox/lox,
ApoEcre eliminate leptin in the urine (Figure 25). This finding was confirmed using
micro-PET imaging (Figure 26). Thus, megalin, and not ObR, is required for the uptake
and degradation of leptin in the kidney following filtration of the protein at the
glomerulus.
To our knowledge, this is the first report of a non-ObR cell surface receptor
playing a role in leptin physiology. Our results have broader implications since megalin is
expressed in several organs such as lung, intestine, thyroid, parathyroid, placenta,
endometrium, yolk sac, testicle, ovary and in brain microvessels and choroid plexus230,
anatomical structures that are part of the blood brain barrier that leptin actively crosses to
enter in the brain167. For example, our findings support the need for intensive
investigation on the interaction between leptin and megalin at the blood brain barrier174.
We speculate that megalin mediated uptake and transport of leptin in different tissues and
organs could become a target for pharmacological intervention useful for the treatment of
obese patients.

5.4 Leptin in hematopoiesis
Our biodistribution results support the idea that leptin plays a significant role in
hematopoiesis and immunity in mammals. In mice, leptin binds to bone marrow and
spleen, in an ObR dependant manner (Table 3a, Figure 28). One previous biodistribution
study also found uptake of 125I-leptin in the bone marrow92. By PET imaging using 68GaDOTA-leptin in rats, leptin localized to the proximal femur, a site of bone marrow
production in rodents (fig 19). In rhesus macaques, binding to the spleen is very low,
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while uptake in bone marrow is high (16% of total injected dose, Figures 33-34). These
results are consistent with binding of leptin to tissues undergoing active hematopoiesis: in
mice, spleen and bone marrow are sites of hematopoiesis, while in adult rhesus macaques
and humans only the bone marrow is193. An ex vivo tissue section binding study found
high affinity binding sites using 125I-leptin in the fetal liver in mice, which decrease
during development, as binding in the spleen increases83. This pattern of receptor
distribution follows the development of hematopoietic tissues in mice, where the liver
serves as the sites of hematopoiesis in utero, while the spleen and bone marrow serve this
function in adult mice. Thus, taken together with the previous data, leptin binds to sites of
active hematopoiesis, in an ObR dependant manner, in mice, rats, and rhesus macaques.
Several lines of evidence support an important role for leptin in regulating
hematopoiesis and immune function231,232. Firstly, humans lacking a functional leptin
gene are predisposed to frequent upper respiratory tract infections, and have reduced
CD4+ T-cells. Furthermore, lymphocytes isolated from these patients have reduced
proliferative responses, and dysregulated cytokine production consistent with an excess
of Th2/regulatory cytokines. This abnormal phenotype is corrected by treatment with
recombinant leptin21. A similar syndrome is seen in ob and db mice, which have severely
impaired humoral and cell-mediated immunity233,234. Ob mice have substantially reduced
lymphopoiesis, particularly in the B-cell compartment, which is corrected by leptin
treatment235. Furthermore, Ob mice are protected against experimental autoimmune
encephalitis69. Thus, leptin is clearly required for normal immune function in humans and
rodents.
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Leptin also has effects on hematopoietic stem cells and mature immune cells in
vitro. Leptin stimulates proliferation and granulocyte-macrophage colony formation in
hematopoietic stem cells in vitro236. Leptin receptors are abundantly expressed by
hematopoietic stem cells, and marrow isolated from db mice has a blunted response to
leptin treatment63,237. Furthermore, leptin has clear effects on immune cells in vitro: it
promotes the secretion of pro-inflammatory Th1 cytokines (such as IFN-γ) at the expense
of Th2 cytokines (such as IL-4), and it substantially increases the proliferation of naïve
T-cells62. Additionally, leptin activates monocytes, augmenting the release of Th1
cytokines238. Taken together, these data indicate that leptin plays a role in augmenting
hematopoiesis (particularly lymphopoiesis) and plays a permissive role in immunity.
An interesting question raised by our biodistribution results is to what extent
leptin is moderating the physiology of hematopoiesis and immunity directly, via receptors
on bone marrow and mature immune cells. Our finding of extensive uptake of leptin in
hematopoietic tissues in mice, rats and rhesus macaques, combined with ample evidence
of leptin’s effects on immune and hematopoietic cells in vitro62,236-239, suggests that a key
role of leptin in augmenting hematopoiesis and immunity is a direct effect on the
hematopoietic cells. However, lethally irradiated db mice, with a wild type bone marrow
transplant were unable to reconstitute a normal immune system, while db to wild type
bone marrow chimeras had an essentially normal immune system240. These results
suggest that the immune deficiency seen in db mice is not intrinsic to immune cells, but
rather that it is due to a deficiency in either the bone marrow microenvironment or
elsewhere in the organism. However, these results must be interpreted with caution, as
the lethal irradiation technique does not completely destroy the host immune system, and

114

the degree of chimerism in these experiments is only 80%. Thus, it is possible that the
remaining 20% of wild type immune cells mask the immune deficit. Furthermore, leptin
can still induce granulocyte-macrophage colony formation, albeit to a lesser extent, in
marrow isolated from db mice236. Thus, it is possible that leptin may still function via the
truncated ObR16 in db mouse marrow, or that it may act via an alternative mechanism in
these cells. One potential approach to overcome these limitations would be to use
lymphocyte specific promoters241 to knock out ObR in specific hematopoietic tissues, or
alternatively to drive ObRb expression in these tissues in mice lacking all isoforms of the
leptin receptor. Thus, to date the relative contribution of leptin signaling to immune
function via direct action on blood cells and precursors, versus indirect actions via other
tissues, has not been fully addressed.
A second question raised by our study is which cell types leptin is binding to in
the bone marrow. This question was partially addressed by Gainsford et al., who
incubated a human bone marrow preparation with 125I leptin in vitro, and then
characterized which cell types took up the tracer by autoradiography239. In this assay, a
variety of precursors, including blasts, myelocyte precursors, promonocytes, and
monocytes took up the tracer. Only a small subset of lymphocytes took up the tracer, and
some of these had “intense labeling.” These results imply that leptin has different effects
on different lymphocyte populations. A molecular characterization of leptin-binding to
immune and hematopoietic cells using cell-specific antigens has not been performed to
date. It is likely that the question of the specific substrates of leptin action in
hematopoietic and immune tissues could be answered by flow cytometry using
fluorescently labeled leptin in combination with cell-type specific antibodies.
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A final intriguing possibility raised by our finding of intense uptake of leptin in
the bone marrow is the possibility of using this tracer as a diagnostic imaging agent. In
humans, leptin receptor is overexpressed in a subset of patients with acute myelogenous
leukemia (AML), chronic myelogenous leukemia (CML) and in acute promyelocytic
leukemia (APL)242-244. Leptin receptor is also expressed in solid tumors, including
endometrial245, hepatocellular,246 breast,247-249 colorectal,250 and renal251 cancers. Leptin
receptor is being actively investigated as a marker for these cancers249,251,252, and it is
likely that using the tracers 68Ga-DOTA-leptin and 18F-FBA-leptin as an imaging agent in
patients with these tumors could aid in visualizing, staging, and diagnosing these
malignancies.

Section 5.5 Leptin transport into the brain
We found that uptake of leptin in the brain occurs at extremely low levels, with
uptake values of between 0.1 to 0.4% of injected dose per gram of tissue in mice (Table
3A). These results are consistent with previous reports of leptin transport into the
brain17,92. These experiments reveal that leptin is taken up in the brain in a saturable
manner in an ObR dependant manner. To our knowledge, these results represent the first
conclusive report that leptin uptake in the brain is dependant on ObR in vivo, as all
previous experiments used ObR-deficient mice with high circulating levels of leptin,
which would saturate any binding sites.
One possibility is that ObR itself mediates the transport of leptin across the BBB,
as ObRa is abundantly expressed on choroid plexus and cerebral microvessels39.
However, Banks et al. found no difference in the transport of leptin across the BBB in a
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perfusion model in the Koletsky rat, which lacks functional leptin receptors
altogether40,253. In this model, the brain is perfused with a saline solution containing
leptin, and thusly corrects for serum components interfering with leptin brain transport. In
contrast, Hileman et al found that mice lacking ObR had reduced transport of the protein
in a similar brain perfusion system39. Thus, although the suggestion that ObR mediates
the transport across the BBB is over a decade old, it has not been conclusively proven or
disproven.
An intriguing question raised by our experiments and that of others is the relative
role of megalin in the transport of leptin into the brain. A recent report showed that a
transfection of a virus expressing siRNA directed against megalin reduced transport of
leptin into the brain in mice174. Based on these results, the authors concluded that megalin
mediates the transport of leptin into the CSF. These results are supported by our own
finding that megalin mediates the uptake of leptin in the kidney. It is possible that either
or both ObR and megalin mediate the transport of leptin into the brain, or that there is
cross-talk between these systems. Furthermore, Banks et al. have suggested that there are
two mechanisms of transport into the brain, a saturable and a non saturable one, and that
transport varied in different regions of the brain182. Similarly, Thomas et al. found a
saturable and non-saturable component of leptin transport into the CSF in a sheep choroid
plexus model216. The molecular identity of these transporters remains obscure.
Nevertheless, it is likely that either megalin or ObR, or both acting together, play a role in
this mechanism. Animals with deletions of these receptors in the choroid plexus and
capillary endothelium could be used to evaluate this hypothesis.
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Chapter 6. Materials and methods

General Methods
Amino acid derivatives, resin and coupling reagents were purchased from Novabiochem
(San Diego, CA) unless otherwise indicated. Boc-aminooxyacetic acid was purchased
from Sigma-Aldrich (Milwaukee, WI). All other chemicals were purchased from SigmaAldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). Recombinant murine
leptin was a gift of Amgen (Thousand Oaks, CA), or Amylin (San Diego, CA).
Analytical gradient reversed phase HPLC was performed on a Hewlett Packard 1100
series instrument and a Vydac C18 or C4 column (5 micron, 4 X 150 mm). Flow rate was
1 mL/min and detection was at 214 and 280 nm. Preparative scale HPLC was performed
on a Waters Delta Prep 4000 fitted with a Waters 486 tunable absorbance detector and
using either a Vydac C4 process scale column (5 x 25 cm) at 30 mL/min, a Vydac C18
process scale column (5 x 25 cm) at 30 mL/min, or a Vydac C4 semiprep scale column (1
x 25 cm) at 5 mL/min. Radiochemical HPLC was performed on a Varian ProStar series
instrument fitted with a model 320 UV detector and a Bioscan flowcount radiodetector
(Bioscan Inc., Washington D.C.), and either a Vydac analytical C4 column (5 micron, 4
X 150 mm) at 1 mL/minute or a Waters μBondapak C18 (7.8 x 300 mm) column at 3
mL/min as indicated. HPLC mobile phase buffers A and B were 0.1% trifluoroacetic acid
in water, and 90% acetonitrile, 0.1% trifluoroacetic acid in water, respectively.
Electrospray mass spectrometry was routinely used on all peptides and proteins, using a
Sciex API-100 single quadrapole spectrometer. Thin layer chromatographic (TLC)
analysis was conducted using normal phase silica 60, F254, 250 μm, 2.5 x 7.5 cm plates
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(Spectrum Chemical, Gardena, CA). Quantification of radiochemical thin layer
chromatography plates was performed on a Bioscan Mini-Scan TLC scanner (Bioscan,
Washington, D.C.). All enzymes involved in the construction of the plasmids were
obtained from New England Biolabs (Ipswich, MA). All molecular biology kits were
obtained from Qiagen unless otherwise specified. Metal free buffers were prepared by
pre-treatment of the buffers with Chelex 100 resin (Biorad, Hercules, CA).

Animal Maintenance
Wild type C57BL/6J and Ob/ob mice were obtained from Jackson laboratory (Bar
Harbor, ME). Megalinlox/lox, ApoEcre and megalinlox/lox mice were obtained from Dr. T.
Willnow (Max-Delbrueck Molecular Cardiovascular Research and Medical Faculty, Free
University of Berlin175.) Rats used for PET scans were male Sprague-Dawley purchased
from Charles River Laboratories. ObRΔ/ob/ob mice were generated in our laboratory
crossing heterozygote mice for both the leptin receptor mutation (ObRΔ18) and leptin
gene mutation (ob). All mice were maintained in cages in temperature controlled rooms.
All animals were subjected to a 12 h light/dark cycle. Procedures and measurements were
performed between 10:00 and 17:00 hours. Animal care and experiments were conducted
in accordance with approved guidelines of The Rockefeller University.
Rhesus macaque subjects were two gonadally intact adult male rhesus monkeys
(Macaca mulatta). Subjects were approximately 14 years of age and weighed in the range
10-12 kg. Subjects were housed in a stable colony and were previously exposed to the
experimental situation (e.g., pole and collar training, transfer into transport cage etc.).
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Titration of leptin labeling with DOTA-NHS
Murine leptin (Amgen/Amylin) at 13.1 mg/mL was diluted to 5 mg/mL using 100
mM metal free sodium phosphate pH 7.0. To 10 µL of the resulting solution was added 2
µL of 10 mg/mL DOTA-NHS (Macrocyclics Inc., 40 nmol, 5 equivalents), or 4 µL 10
mg/mL DOTA-NHS (80 nmol, 10 equivalents). Additionally, to 262 µL of the same
solution was added 100 equivalents of DOTA-NHS (8.2 µmol, 4.12 mg), and the pH was
adjusted to 7.5 with metal free 1N NaOH. The reactions were allowed to proceed 1-3
hours at 4 degrees, and then analyzed by C4 RP-HPLC on a 0-100% B gradient, and by
ESI-MS.

Preparation of DOTA-leptin
A lysine-directed labeling approach using DOTA-NHS ester (Macrocyclics) was
employed. Briefly, to 100 µL mouse leptin solution at 13.1 mg/mL (Amylin) was added
162 µL metal free (by chelex resin treatment, Biorad) 100 mM sodium phosphate pH 7.5
(final concentration of 5 mg/mL). To this solution was as added 100 equivalents of
DOTA-NHS (8.2 µmol, 4.1 mg), and the pH adjusted to 7.5 using 1N NaOH. The
reaction proceeded for 3 h at 4 °C at which point it was purified by HPLC using a
Hewlett Packard 1100 series instrument and a Vydac C4 column (5 micron, 4 X 150 mm)
on a 45-60%B gradient (where buffer A is 0.1% trifluoroacetic acid in water, and buffer
B is 90% acetonitrile, 0.1% trifluoroacetic acid in water.) The product was characterized
by ESI-MS on a Sciex API-100 single quadrapole spectrometer, which indicated the
incorporation of 2-6 DOTA moieties per leptin molecule. The solution was separated to 8
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aliquots of DOTA-leptin and lyophilized.

Generation of a Stable Cell Line Overexpressing Leptin Receptor Long Isoform
(Ob-Rb) and a Stat3-Responsive Element-Luciferase Reporter
A stable Flp-In 293 cell line254 expressing the long isoform of the leptin receptor
(Ob-Rb) that is capable of full signaling (kind donation of Dr. Cai Li, University of Texas
Southwestern) was stably transfected with a p4xm67 luciferase plasmid, containing a
STAT3 responsive element and luciferase DNA (kindly provided by Dr Jim Darnell, The
Rockefeller University). Cells were transfected with p4xm67 luciferase and a puromicin
resistance plasmid following the Lipofectamine 2000 method (Invitrogen). Stable
integrants were selected in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum and puromicin (1.5 μg/ml) for about 4 weeks. Single cell clones were then
selected for leptin induced luciferase production and the clone with the best response to
leptin used for further experiments.

Luciferase Reporter Assay of Leptin Receptor Activation
Ob-Rb-STAT3-luciferase cells were seeded into 24-well plates. At a confluence
of 80% the cells were washed and replaced with serum-free medium. After 4 hours the
medium was changed and replaced by serum-free medium containing dilutions of leptin
or the appropriate semisynthetic derivative. Samples were assayed in duplicate for every
dilution. After 24 hours cells were collected and luciferase activity measured in cell
lysate using a luciferase assay system (Promega).
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Leptin Administration to ob/ob Mice
Leptin or its semisynthetic derivatives were administered continuously with mini
osmotic pumps (Alzet, Cupertino, CA, model 2002) to Ob/ob mice with an exchange rate
of 450 ng/h for ob/ob mice. Pumps were filled aseptically according to the manufacturer
instructions with either sterile PBS solution, leptin, or leptin derivatives. Recombinant
leptin or leptin derivatives were diluted in sterile PBS buffer. Before surgery, pumps
were incubated overnight in a sterile 0.9 % NaCl solution at 37 °C to achieve immediate
and constant pumping rate at the time of implantation. During surgery mice were
anesthetized with isofluorane. Pumps were implanted subcutaneously in the interscapular
region of the mice. Body weight was measured on a daily basis following surgery.

68

Ga labeling of DOTA-leptin.
One DOTA-leptin aliquot consisting of approximately 70-100 µg of protein (see

above) was resuspended in 40 µL of metal free 15 mM HCl. After incubation for 10
minutes on ice to allow full resuspension of the protein, 10 µL of 1.2M sodium acetate
(pH 4.5) was added. Immediately prior to addition of the 68Ga solution, the protein
solution was centrifuged for 2 minutes at 10,000 x g to remove insoluble components.
DOTA-leptin was labeled using 68Ga eluted from a 68Ge generator (Isotope
Products Laboratories) using a previously described procedure199 with modifications. We
found that reproducible labeling results were obtained by eluting the generator the
evening prior to labeling, presumably to remove impurities. The gallium generator was
eluted with 7 mL of 1M metal free HCl. The solution was diluted with 7 mL of
concentrated HCl (trace metal grade, Fisher), and applied to 150 µL settled volume of
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AG1-X8 resin (Biorad). The 68Ga was then eluted from the resin using 300 µL 15 mM
HCl and followed by 100 µL of 15 mM HCl. The dilute acid solution was evaporated at
160 degrees, and the 68Ga was subsequently resuspended in 40 µL of metal free 15 mM
HCl. The 68Ga solution was then added to the leptin-DOTA solution (above), and
incubated in a 35 °C water bath for 20 minutes. The solution was then centrifuged for 1
min at 10,000 x g, and the supernatant added to 2 µL of 0.1M
diethylenetriaminepentaacetic acid (DTPA). After 2 min the solution was transferred to a
micro bio-spin P6 column (Biorad), which had been pre-equilibrated with PBS according
to the manufacturer’s instructions. The 68Ga -DOTA-leptin was eluted from the column
by centrifuging at 1000 x g for 4 minutes. Following elution the solution was diluted to
an appropriate volume for injection in PBS (typically to 0.5-1 mL), and filtered through a
0.22 µm filter. The specific activity of the conjugate at the end of synthesis was 9.1 ± 4.2
GBq/µmol (s.d., n = 30 syntheses) at greater than 90% pure as determined by
radiochemical HPLC and iTLC. The amount of total protein in the reaction was
determined by BCA assay (Pierce).

Radiochemical HPLC and iTLC analysis
Radiochemical HPLC was performed on a Varian ProStar series instrument fitted
with a model 320 UV detector and a Bioscan flowcount radiodetector (Bioscan Inc.,
Washington D.C.), and a Vydac analytical C4 column (5 micron, 4 X 150 mm) at 1
mL/minute. HPLC mobile phase buffers A and B were 0.1% trifluoroacetic acid in water,
and 90% acetonitrile, 0.1% trifluoroacetic acid in water, respectively. Linear gradients
from 0-100%B over 30 minutes with a 2 minute isocratic were used.
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iTLC was performed using ITLC SG silica impregnated glass fiber sheets (Pall,
East Hill, NY), with 5 mM diethylenetriaminepentaacetic acid (DTPA) as an eluant.
Quantification of radiochemical thin layer chromatography plates was performed on a
Bioscan Mini-Scan TLC scanner (Bioscan, Washington, D.C.).

Stability of 18F-FBA-leptin 5 and 68Ga-DOTA-leptin in vivo
Approximately 20 MBq of 18F-FBA-leptin 5 or 68Ga-DOTA-leptin was injected
into either ob/ob or wild type mice via the tail vein. After 20 - 30 minutes (as indicated in
the text), the animals were sacrificed and 500 μL of whole blood was collected. The
blood was centrifuged for 15 minutes at 7000 rpm, and the supernatant injected on a C4
analytical HPLC.
Radioactive Cell Binding Experiment
ObRb expressing cells were grown overnight in suspension in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum at 37 °C and 5% CO2. Cell
viability and concentration was then determined using trypan blue staining. Cells were
washed with serum free medium and re-suspended in HBSS supplemented with 0.1%
BSA at a final concentration of 20 million/mL. For each cell binding assay, 750 μL of
cell suspension was incubated with a constant amount of radiolabeled leptin
corresponding to 80,000 cpm of radioactivity (either 68Ga-DOTA-leptin or 18F-FBAleptin) + 60 μg of cold leptin. The concentration of the labeled leptin was determined
using the BCA method (BCA protein Assay Kit, microplate procedure, Pierce).
Following incubation of the cells at room temperature for 2 hours at constant agitation,
the cell suspension was washed twice with 0.5 mL of HBSS with 0.1% BSA and
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centrifuged at 2000 rpm for 5 minutes. The radioactivity associated with cell pellet (cell
bound activity) was determined by counting the tubes in a gamma counter with
corresponding standards and blanks.
Cloning of Leptin(1-146)-GyrA-His6
The sequence encoding the chitin binding domain in the pTXB vector (New
England Biolabs, Ipswich, MA) was replaced with a His6 tag sequence to facilitate
protein purification under denaturing conditions. Synthetic oligonucleotides encoding a
His6 tag flanked by AgeI and PstI restriction sites (sense strand; 5’CCGGTGGAGCGCATCATCATCATCATCATGGAGCGTAACTGCA and antisense
strand; 3’-GTTACGCTCCATGATGATGATGATGATGCGCTCCA) were
phosphorylated using T4 DNA kinase and annealed. The pTXB vector was digested with
AgeI and PstI, and the annealed His-oligos inserted using T4 ligase to give plasmid
pGyrAHis, the identity of which was verified by sequencing. cDNA encoding leptin(1146) was amplified by PCR from a leptin-EGFP plasmid (obtained from A. Zeigerer,
Friedman lab) using forward and reverse primers
(GGAATTCCATATGGTGCCTATCCAGAAAGTCCAGG
and GGACTAGTGCATCTCCCGTGATGCATTCAGGGCTAACATCCAACTG,
respectively) encoding the NdeI and SpeI restriction sites. The PCR product was purified
by gel extraction and ligated into the pre-digested pGyrAHis plasmid using T4 ligase to
give the plasmid pLeptin-GyrA, the identity of which was verified by sequencing.
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Overexpression and purification of Leptin(1-146)-GyrA-His6
E. coli BL21(DE3) cells (Novagen, Darmstadt, Germany) were transformed using
the plasmid pLeptin-GyrA. Cells were grown to an OD600 of 15-25 in a Bioflo 3000
Batch/Continuous bioreactor (New Brunswick Scientific, Edison, NJ) in superbroth
media (Qbiogene, Irvine, CA) with 50 μg/mL ampicillin. The culture medium was
supplemented with oxygen to keep oxygen gas levels constant at 30% and agitated at 350
RPM. The pH was maintained at 7.0 automatically using 5N sodium hydroxide. The
culture medium was supplemented with 2 mL/min 50% glucose and 2 mL/min 3X
superbroth solution during growth. Overexpression was induced with 1 mM IPTG, and
the flow of glucose and superbroth was increased up to 10 mL/min. After four hours of
induction at 37 °C, the cells were harvested by centrifugation. Using this protocol 200250g of biomass was typically obtained per culture prep.
The cells were resuspended in lysis buffer consisting of 1% triton, 50 mM sodium
phosphate buffer, pH 7.0, 200 mM sodium chloride supplemented with one complete
protease inhibitor tablet, EDTA free (Roche, Basel, Switzerland) per 50 mL of buffer.
The cells were lysed by passage through a French Press (Emulsiflex C5 homogenizer,
Avestin, Ottawa, Canada.). The inclusion bodies were separated by centrifugation at
16,000 rpm for 30 minutes, and subsequently resuspended overnight in one volume
(relative to the cell pellet) of resuspension buffer consisting of 8 M urea, 20 mM
imidazole, 150 mM sodium chloride, 100 mM sodium phosphate, pH 7.5. This
suspension was centrifuged again at 16,000 RPM for 30 minutes to remove insoluble
debris, and applied to 100 mL of Ni-NTA beads which were pre-equilibrated with
resuspension buffer supplemented with 20 mM imidazole. The beads were then washed
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with resuspension buffer supplemented with 20 mM imidazole, and the fusion protein
was eluted from the column with 10 x 50 mL fractions of resuspension buffer
supplemented with 500 mM imidazole. The fractions were analyzed by SDS-PAGE and
those containing the 39 kDa fusion protein were pooled.

Optimization of intein cleavage
100 μL of pure leptin-GyrA-His6 was refolded by dialysis overnight using four
buffer changes of 250 mL, in buffer containing 200 mM sodium phosphate, 200 mM
NaCl, 5 mM EDTA, pH 7.0, in the presence of varying additives, including 1 & 2M
guanidine, and 2, 3, 4 and 5M Urea. Following dialysis, ethanethiol was added to 3%,
and the samples were cleaved overnight at room temperature or at 4° C. Samples were
analyzed by SDS-PAGE and Coomassie staining.

Generation of Leptin(1-146) α-thioester, 1
The combined Leptin(1-146)-GyrA-His6 fractions were refolded by extensive dialysis
against 4 M urea, 100 mM sodium phosphate, 150 mM sodium chloride pH 7.0 at 4 °C.
The first dialysis buffer was further supplemented with 10 mM EDTA to remove trace
amounts of contaminating nickel. Intein cleavage to form the leptin (1-146) α-thioester 1
was initiated by adding sodium 2-mercaptoethane sulfonate to a final concentration of
100 mM. Cleavage was allowed to proceed for 2 days at 4 °C. The crude cleavage
reaction was reapplied to 100 mL of nickel-NTA beads, which were pre-equilibrated with
dialysis buffer supplemented with 20 mM imidazole. The beads were washed with
dialysis buffer supplemented with 20 mM imidazole and 100 mM sodium 2-
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mercaptoethane sulfonate. The pooled flowthrough and washes from the Ni-NTA column
containing principally the leptin(1-146) α-thioester 1 were then purified by process scale
C4 RP-HPLC using a gradient of 50-65% buffer B. Fractions were analyzed by analytical
RP-HPLC and ESI-MS, and those containing pure leptin α-thioester 1 were pooled and
lyophilized. Residual uncleaved fusion protein on the Ni-NTA column could be
recovered from the column by elution with 8 M urea, 500 mM imidazole, 500 mM
sodium chloride, 100 mM sodium phosphate pH 7.0, and refolded and recleaved as
above. Using this procedure, ~60 mg of pure leptin(1-146) a-α-thioester 1 could be
obtained from an initial 5L culture.

Synthesis of native murine leptin by EPL
Leptin-GyrA-His6 was expressed, purified, and refolded as indicated above. EPL
with cysteine was initiated using 100 mM sodium 2-mercaptoethanesulfonate and 10 mM
cysteine, and the reaction was allowed to proceed for 3 days at 4 °C. After the reaction
was complete, it was diluted to 0.25 mg/mL in 6 M guanidine hydrochloride, 20 mM tris
pH 7.4, 5 mM dithiothreitol. The product was then dialyzed at 4 °C sequentially against 6
M urea, 2.5 mM dithiothreitol, 2.5 mM 2-mercaptoethanol, 20 mM tris pH 7.4, then
against 4 and 2 M urea containing 5 mM 2-mercaptoethanol, 20 mM tris pH 7.4, then
against 20 mM tris pH 7.4, and finally overnight against 20 mM tris pH 7.4, 5 mM
oxidized glutathione, 0.5 mM reduced glutathione, 150 mM sodium chloride. The crude
refolded mixture was purified on a C4 semiprep RP-HPLC column using a gradient of
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45-60% buffer B (buffer A = 0.1% TFA in water, buffer B = 90% acetonitrile, 0.1% TFA
in water.) Fractions containing pure murine leptin were pooled and lyophilized.

Synthesis of Peptide 2
The peptide was prepared using manual Fmoc-based solid phase peptide
synthesis, as indicated on Scheme 3. Agitation was achieved using a flow of nitrogen gas.
Fmoc deprotection was achieved using 5 mL of 20% piperidine in DMF for 3 minutes
followed by another treatment for 10 minutes. The resin was acetylated after every
coupling using 5 mL of 10% acetic anhydride, 10% diisopropylethylamine (DIEA) in
DMF for 10 minutes. Washes with DMF were performed in between all coupling,
acetylation, and deprotection steps.
Fmoc-Lys(ivDde) (0.379 g, 0.66 mmoles) was coupled to Rink amide AM resin
(420 mg, 0.71 mmol/g) using 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU, 0.228 g, 0.6 mmoles), 0.5 mL DIEA, in 4 mL DMF for two
hours. After capping and deprotection, Fmoc-NH-PEG2(20 atoms)-COOH linker (0.2 g,
0.36 mmoles) was coupled to the resin using HBTU (0.125 g, 0.33 mmoles), 0.5 mL
DIEA in 4 mL DMF for two hours. The coupling reaction was repeated. Following
capping and deprotection, Boc-Cys(Trt)-OH (1.02 g, 2.2 mmoles) was coupled using
diisopropylcarbodiimide (310 μL, 2 mmoles), N-hydroxybenzotriazole (0.270 g, 2
mmoles) for 20 minutes. The coupling was then repeated. The ivDde group was
deprotected using 2% hydrazine in DMF three times for one hour. Boc-aminooxyacetic
acid (0.460 g, 2.4 mmoles) was then coupled using DIC (370 μL, 2.4 mmoles) for 10
minutes as described255. The resin was washed with DCM and dried. Cleavage from the
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resin and deprotection was achieved using 5 mL of 1% triisopropyl silane, 2.5%
ethanedithiol, 2.5% water in trifluoroacetic acid (TFA) for 2.5 hours. The peptide was
precipitated using 50 mL of 5% 2-mercaptoethanol in diethyl ether, centrifuged at 4800
rpm for 10 minutes, resuspended in 5 mL of HPLC buffer A, and lyophilized. The crude
residue was then purified by process scale RP-HPLC on a C18 column using a gradient
of 5-20% B. Fractions containing the purified peptide 2 were identified by HPLC/MS,
pooled, and lyophilized. Yield from 0.3 mmol scale: 120 mg, (0.19 mmol), 63%.

Semisynthesis of Aminooxy-leptin 4
Leptin(1-146) a-α-thioester 1 was dissolved to a concentration of 20 mg/mL in 6
M guanidine hydrochloride, 100 mM sodium 2-mercaptoethane sulfonate, 200 mM
sodium phosphate, 150 mM sodium chloride, pH 7.2. Peptide 2 (10-20 mg, 25
equivalents) was added to 10 mg/mL, and the pH was adjusted to 7.2 using 1 N NaOH.
After overnight reaction at room temperature, the crude mixture containing unfolded
aminooxy-leptin derivative 3 was diluted to 0.25 mg/mL in 6 M guanidine hydrochloride,
20 mM tris pH 7.4, 5 mM dithiothreitol. The product was then dialyzed at 4 °C
sequentially against 6 M urea, 2.5 mM dithiothreitol, 2.5 mM 2-mercaptoethanol, 500
μM aminooxyacetic acid, 20 mM tris pH 7.4, then against 4 and 2 M urea containing 5
mM 2-mercaptoethanol, 500 μM aminooxyacetic acid, 20 mM tris pH 7.4, then against
500 μM aminooxyacetic acid, 20 mM tris pH 7.4, and finally overnight against 20 mM
tris pH 7.4, 5 mM oxidized glutathione, 0.5 mM reduced glutathione, 500 μM
aminooxyacetic acid, 150 mM sodium chloride. The crude refolded mixture was purified
on a C4 semiprep RP-HPLC column using a gradient of 45-60% buffer B (buffer A =

130

0.1% TFA in water, buffer B = 90% acetonitrile, 0.1% TFA in water.) Fractions
containing pure refolded AOA-leptin 4 were identified by HPLC and ESI-MS and pooled
and lyophilized into 250 μg aliquots. Yield from a 1 μmol scale: 5 mg, (0.3 μmol), 30%.

Tryptic Digestion of Aminooxy-leptin 4 and Recombinant Leptin
20 μg of sequencing grade trypsin (Promega, Madison, WI) was dissolved in 100
μL of trypsin resuspension buffer (provided by the manufacturer), and incubated at 30 °C
for 15 minutes. The trypsin solution was added to 150 μg of either aminooxy-leptin 4
(dissolved in 15 mM HCl) or recombinant leptin (Amgen, Thousand Oaks, CA), and the
pH was adjusted to 8.3 using 1 M sodium bicarbonate. The reaction was incubated at 37
°C for 3 hours, and analyzed by analytical RP-HPLC on a C4 analytical column using a
gradient of 0-100% B. Peaks were collected and identified by ESI-MS.

Synthesis of 19FBA-leptin 5
Aminooxy-leptin 4 (5 mg, 0.3 mmole) was dissolved in 2 mL of 15 mM HCl. 250
μL 1 M sodium acetate pH 4.5 was added, followed by 250 μL of 10 mM 4fluorobenzaldehyde in DMF. The reaction was vortexed, and incubated at 4 °C overnight.
The reaction was then purified by C4 semipreperative RP-HPLC on a gradient of 46-61%
B. Fractions containing pure FBA-leptin 5 were pooled and lyophilized, yielding 1.7 mg
pure protein (Yield of 34%).
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Synthesis and Reformulation of 18F-FBA
The radiosynthesis of 18F-FBA was accomplished essentially as previously
described, however in order to facilitate labeling of leptin, which precipitates in solutions
containing a high proportion of organic solvents, it was reformulated into 5 μL of DMF.
The precursor (4-formylphenyl)trimethylammonium trifluoromethanesulfonate was
synthesized as previously described155. This precursor was dried under vacuum and stored
under argon atmosphere. Cyclotron produced 18F in 18O water was loaded onto a QMA
light cartridge (Waters), which had been preconditioned with 5 mL 0.5M potassium
carbonate and 10 mL water. The cartridge was eluted with a solution of 20 mg kryptofix
222 (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane), 2 mg potassium
carbonate in 1:1 acetonitrile:water into a 3 mL reactivial (Pierce, Rockford, IL) equipped
with a stir bar. The resulting solution was evaporated at 95 °C with a gentle nitrogen
stream, and dried azeotropically using 3 x 1 mL dry acetonitrile. The resulting solid was
resuspended in 400 μL of dry DMSO and transferred to a second 3 mL reactivial
equipped with a stir bar and containing 1-2 mg of (4-formylphenyl)trimethylammonium
trifluoromethanesulfonate. The vial was incubated for 8 minutes at 120 °C, and then
cooled to room temperature. The reaction was then diluted with 1.5 mL of water, and
filtered through a GHP filter (Pall, East Hill, NY) and loaded on a Waters μBondapak
C18 (7.8 x 300 mm) semiprep column, and eluted isocratically using 13:87
acetonitrile:water with 0.1% TFA at a flow rate of 3 mL/min. The peak eluting at 14
minutes was diluted with 15 mL water, and loaded onto a C18 sep-pak plus cartridge
(Waters). The cartridge was then eluted with 1 mL of diethyl ether. A small amount of
DMF (5 μL) was added during this step to minimize loss of the FBA during evaporation.

132

The diethyl ether was then evaporated at 45° C, leaving a small organic residue (about 510 μL in a typical reaction). The product had the same Rf in 3:1 hexanes:ethyl acetate as
authentic 4-fluorobenzaldehyde (0.65) and the same retention time on C18 HPLC as the
authentic sample. Starting from 9.25-13 GBq, typically 1.3-1.85 GBq of reformulated
18

FBA could be recovered with a synthesis time of 90 minutes.

Rate of Oximation of Aminooxyleptin 4 with 18F-FBA
Lyophilized aminooxy-leptin 4 (150 μg, 9.1 nmol) was dissolved in 55 μL 15 mM
HCl, and 15 μL of either 0.5 M sodium acetate pH 4.5 or anilinium acetate pH 4.5 was
added, giving a final volume of 70 μL (final concentration of 4 = 125 μM). 2 μL of 18FFBA in DMF (prepared as described in the supporting information) was added to each
reaction, which was vortexed and placed on ice. Aliquots of the reaction were spotted on
TLC plates at the indicated times and run with 4:1 DCM methanol with 2% acetic acid.
18

F-FBA leptin 5 was retained at the origin while 18F-FBA migrated at the solvent front.

At t = 30 minutes, a small portion of the anilinium acetate reaction was injected on a C4
analytical HPLC column and eluted on a 0-100% B gradient over 30 minutes. The 18FFBA eluted at 3.5 minutes while the 18F-FBA-leptin 5 eluted at 21 minutes on this
gradient.

Synthesis of 18F-FBA-leptin 5
Lyophilized aminooxy-leptin 4 (500 μg, 30 nmol) was dissolved in 100 μL of 15
mM HCl. To this solution was added 25 μL of 0.5 M anilinium acetate, pH 4.5. The
aforementioned DMF solution of 18F-FBA was then added, and the mixture was vortexed
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and incubated on ice for 15 minutes. The reaction was then purified through two micro
bio-spin P-6 columns (Biorad, Hercules, CA), which had been pre-equilibrated with PBS
according to the manufacturer’s instructions. The eluate from the columns was filtered
though a 0.22 μM filter. The purity of the oxime product was analyzed by both RP-HPLC
using a 0-100% B gradient on a C4 analytical column, and by iTLC (ITLC SG silica
impregnated glass fiber sheets, Pall, East Hill, NY) using 1% acetic acid in water as an
eluant. While the labeling yield as detected by HPLC or iTLC was typically over 50%,
the recovered yield was generally 25%, probably due to precipitation of the protein.
Starting from 9.25-13 GBq of aqueous K18F, typically 93-200 MBq of 18F-FBA-leptin 5
was recovered with a total synthesis time of 120 minutes. The total amount of protein in
the final sample was determined using the BCA assay (BCA assay micro plate kit, Pierce,
Rockford, MD). The specific activity at the end of synthesis was 9.25-13 GBq/μmol
(n=4).

Stability of 18F-FBA-leptin 5 in vitro
Approximately 200 kBq of 18F-FBA-leptin 5 in 2 μL was diluted in either 100
mM sodium acetate pH 4.5 (10 mM sodium phosphate, 140 mM sodium chloride, pH
7.4), PBS, or mouse serum. After 60 minutes a sample of each was injected on a C4
analytical HPLC. Integration of the radiochemical HPLC peaks was used to estimate the
purity of the sample, and if no other peaks could be detected above background the
sample was assumed to be greater than 95% pure.
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Synthesis of Isopropylidene-aminooxyacetic acid, succinimide ester (6)
Isopopylidene-aminooxyacetic acid was synthesized as previously described162.
To 500 mg (3.8 mmol) of isopopylidene-aminooxyacetic acid in 30 mL
dichlooromethane, cooled on ice, was added 3.8 mmol (439 mg) N-hydroxysuccinimide,
and 3.8 mmol dicyclohexylcarbodiimide (782.8 mg). The mixture was stirred and
allowed to warm to room temperature overnight. The reaction was filtered to remove
insoluble dicyclohexylurea. The mixture was washed with 1N HCl, water, 1% sodium
bicarbonate, then dried over sodium sulfate. The reaction was then filtered and
evaporated to dryness, and triturated with dichloromethane to remove residual
dicyclohexylurea. Yield 450 mg. 1.97 mmol, 52%. 1H NMR (400 MHz, CDCl3) δ 4.90 (s,
2H), 2.84 (s, 4H), 1.92 (s, 2H), 1.88 (s, 2H).

Conjugation of Isopropylidene-aminooxyacetic, succinimide ester (6) to leptin
To 20 uL of leptin solution (13.1 mg/mL, 16.4 nmol total) was added 32 uL of
100 mM sodium phosphate, pH 7.5, to generate a 5 mg/mL solution. Two 25 uL aliquots
were prepared, and to each aliquot was added either 32.8 or 164 nmol isopropylideneaminooxyacetic acid-NHS (corresponding to 7.5 or 37 µg) in 2.5 µL DMF. The reactions
was allowed to stand for 5-6 hours and then analyzed by RP-HPLC and ESI-MS.

Preparation of aminooxyleptin by lysine side chain modification strategy
To 30 µL of leptin solution at 13.1 mg/mL was added 48 µL of 100 mM sodium
phosphate pH 7.5, and 22.5 µg of isopropylidene-aminooxyacetic acid, succinimide ester
(6) in 5 µL DMF. The reaction was allowed to proceed at room temperature overnight,
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then chilled on ice. The reaction was diluted 1:1 with 1M methoxylamine
hemihydrochloride, and allowed to stand on ice for five hours. The reaction was then
analyzed by HPLC and ESI-MS.

Micro-PET imaging experiments
Imaging was conducted using a MicroPET (Focus TM 220, CTI Concord
Microsystems, LLC) camera, with a bore size of 22 cm and an axial field of view of 7.6
cm. This enables imaging of the entire mouse. The resolution at the center of field of
view (FOV) is <1.3 mm. Mice ranged in age from four to seven months of age.
Following induction of anesthesia with ketamine, each mouse was injected with
3.7-5.4 MBq of 18F-FBA-leptin 5 or 68Ga-DOTA-leptin in the tail vein. Rats were injected
with 6-10 MBq of 68Ga-DOTA-leptin. The distribution of radioactivity was studied by
acquiring dynamic imaging for 30 - 60 minutes. 3D histograms of emission data were
generated (span3, rig difference 47) using dead time correction. Images were
reconstructed using OSEM2D algorithm without any attenuation or scatter correction. All
data were analyzed on PMOD software (Zurich, Switzerland). Regions of interest were
drawn by two independent operators, with similar results.

Metabolite analysis of blood, kidney, and urine by radiochemical HPLC
Approximately 20 MBq of 68Ga -DOTA-leptin or 18F-FBA-leptin was injected into
the appropriate mice via the tail vein after induction of anesthesia with ketaminexylazine. At the indicated time point, the animals were sacrificed, and the blood, urine,
and kidneys harvested. Alternately, urine samples could be recovered by massaging the
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bladder of the mice. Blood samples were centrifuged for 10 min at 8000 RPM (x g) prior
to injection on HPLC. Kidney samples were solubilized by homogenization in 25 mM
Tris pH 7.8, 1% triton X-100, 0.25% BSA, with one Compete mini EDTA-free protease
inhibitor tablet (Roche) added per 10 mL, and centrifuged for 10 minutes at 8000 RPM
prior to injection on HPLC.

Leptin ELISA in urine samples
Urine samples for ELISA were collected at 16 weeks of age. Urine samples from
megalinlox/lox,ApoEcre and megalinlox/lox were diluted 10 fold in calibrator diluent of the
mouse Elisa assay kit (R & D biosystems). A standard curve was build with known
amounts of mouse recombinant leptin diluted in calibrator diluent and 10% urine from
leptin deficient ob/ob mice. Instructions from the manufacturer were followed. Samples
were measured in duplicate, and the assay sensitivity was 0.4 ng/ml.

Western blotting from urine samples
After concentration (10 fold from the starting volume) of the urine of
megalinlox/lox,ApoEcre and megalinlox/lox using vivaspin concentrators (Sartorius), samples
were boiled at 95 C in loading buffer with 10% 2-mercaptoethanol. 30 microliters of each
sample were loaded on a 5-12% acrylamide gel (Biorad) and then transferred to
nitrocellulose membranes for western blot analysis. Blots were blocked in TBST and 5%
milk and then incubated overnight in TBST and 5% milk with rabbit polyclonal antileptin antibody A-20 (Santa Cruz) diluted 1:500. After wash with TBST blot was
incubated with a secondary antibody anti-rabbit IgG conjugated with HRP (GE

137

Healthcare) and ECL reaction performed using ECL plus western blotting detection
system kit (GE Healthcare).

Mouse biodistribution experiments
Approximately 10-15 KBq of 125I-leptin (New England Nuclear, 81.4 GBq/umol,
20 uL of the solution provided by the manufacturer) was diluted in 300 uL of sterile PBS
and injected in the tail vein of the appropriate mouse strains in the presence or absence of
50 uL of murine leptin solution (13.1 mg/mL, Amgen/Amylin). After 15 minutes, the
animals were sacrificed, and tissues were collected and weighed. Radioactivity associated
with each sample was counted in a gamma counter with corresponding standards and
blanks, and residual activity from each injection. The total injected dose was computed
by preparing a standard of 20 uL of the manufacturers solution, and subtracting the
residual dose remaining in the syringe post injection, and the radioactivity in the tail of
the animal.

Subcloning of Rhesus-leptin in a pET 15b vector
Rhesus leptin was subcloned into a PET15b vector, to facilitate purification using
the His6 tag encoded for in the vector. A plasmid containing a synthetic gene, codon
optimized for expression in bacteria, encoding the 146 amino acids of intact rhesus leptin
following a methionine, was ordered from Integrated DNA technologies. The 2 µg of
DNA obtained from the manufacturer was resuspended in 200 µL TE buffer. The cDNA
encoding rhesus leptin was amplified by PCR from using forward and reverse primers
(GGAATTCCATATGGTGCCAATCCAGAAAGTTCA and
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CGGGATCCTTAACAACCCGGAGACAGGTC, respectively) encoding the NdeI and
BamHI restriction sites. The PCR reaction was then purified by gel extraction. The PCR
product and the PET15b vector was digested with NdeI and BamHI, and the vector was
treated with calf intestinal phosphatase. The vector was then purified by gel extraction,
and the PCR product using a PCR purification kit (Qiagen). The rhesus leptin PCR
product was then ligated into the PET15b vector, and transformed into DH5α E. coli. The
identity of the correct plasmids were screened by digestion with NdeI and BamHI, and
confirmed by sequencing.

Expression and purification of rhesus leptin
Expression of rhesus leptin was similar to a previously described protocol256.
PET15b-Rhesus leptin plasmid was transformed into BL21(DE3) E. coli. An overnight
culture was prepared in LB broth, which was diluted the following day by a factor of 100
into 6 X 1L shaking flasks. The bacteria grew at 37°C with shaking at 250 RPM, and
protein expression was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG) at an OD590 of 0.8. After six hours of induction, the cells were harvested by
centrifugation. From a typical prep, 30g of biomass could be obtained. Initial experiments
revealed the presence of an approximately 16 kDa protein in the insoluble fraction, in
induced but not uninduced cells, and thus preparation of the protein from inclusion bodies
was used in future experiments.
The cells were resuspended in two volumes lysis buffer consisting of 1% triton,
50 mM sodium phosphate buffer, pH 7.0, 200 mM sodium chloride supplemented with
one complete protease inhibitor tablet, EDTA free (Roche, Basel, Switzerland) per 50 mL
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of buffer. The cells were lysed by passage through a French Press (Emulsiflex C5
homogenizer, Avestin, Ottawa, Canada.) The inclusion bodies were separated by
centrifugation at 16,000 rpm for 30 minutes, and washed with an equal volume of lysis
buffer. The pellet was subsequently resuspended overnight in one volume (relative to the
cell pellet) of resuspension buffer consisting of 8 M urea, 10 mM imidazole, 500 mM
sodium chloride, 100 mM sodium phosphate, pH 7.5. This suspension was centrifuged
again at 16,000 RPM for 30 minutes to remove insoluble debris, and applied to 25 mL of
Ni-NTA beads which were pre-equilibrated with resuspension buffer supplemented with
10 mM imidazole. The beads were then washed with resuspension buffer supplemented
with 20 mM imidazole, and the fusion protein was eluted from the column with 5 x 20
mL fractions of resuspension buffer supplemented with 500 mM imidazole. The fractions
were analyzed by SDS-PAGE and those containing the fusion protein were pooled. The
protein was then refolded by dropwise infusion of 0.1M Tris pH 7.4 at 1 mL/min over
approximately 90 minutes. Reduced and oxidized glutathione were added to 10 and 1
mM, respectively, and the solution was allowed to stir overnight at 4 °C. The solution
was then centrifuged at 16,000 RPM for 30 minutes to remove insoluble debris, and then
dialyzed against thrombin cleavage buffer consisting of 50 mM tris pH 8.3, 150 mM
NaCl, 2.5 mM CaCl2 in order to remove imidazole. The resulting solution was again
centrifuged to remove insoluble debris, and 100 units of thrombin (Sigma) was added to
the supernatant. Following overnight cleavage at 4 °C, the resulting solution was purified
by process scale C4 RP-HPLC on a 47-62%B gradient. The fractions containing the
intact rhesus leptin were then resuspended in 6M guandine, 100 mM Tris pH 8.0, and
purified by gel filtration on an S75 10/300 GL column, using 10 mM sodium phosphate,
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140 mM NaCl, pH 7.4 as an eluant. From a typical 6L prep, 2 – 3 mg of rhesus leptin
could be obtained using this protocol. The sequence of the final protein is GSHM-rhesus
leptin(1-146).

Rhesus macaque PET-CT imaging experiments
On experiment days, the subjects were individually transported to the PET center
in a purpose - built transfer cage. They were then injected with ketamine (10 mg/kg, i.m.)
and atropine (0.05 mg/kg, i.m). Subjects were then intubated and anesthesia was induced
with isoflurane (3%). Subjects’ vital signs (respiratory rate, heart rate, temperature and
pulse oximetry) were monitored throughout, anesthesia was typically then maintained at
1.5-2% isoflurane for the remainder of the experiment.
The subject was placed supine on a heating pad (37oC) in the bed of the PET
scanner for the remainder of the experiment. Primate PET/CT scans were performed
using a GE Discovery LS PET/CT scanner (GE Healthcare, Waukesha, Wis.). A lowdose CT scan was obtained and the scanner bed was moved into PET
position. Competing cold leptin was administered by a femoral catheter 10 min prior to
injection of the radiotracer. Immediately following an intravenous injection of 0.25-1
mCi of

68

Ga-DOTA-leptin, 4 sequential 18 min whole-body images were obtained (3

beds, 6 minutes each) in 3D acquisition mode. Images were reconstructed using the
FORE-Iterative reconstruction method.
Following completion of the transmission scan, isoflurane was discontinued and
the subject was extubated when gagging reflex is observed, and carefully observed until
recovery (which was rapid and uneventful).
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